{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8796333_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"120-954-513-287-333"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":22718,"type":"PATENT","title":"Citing Vanderbilt Univ publications","description":"Patent documents citing scholarly work of Vanderbilt Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27696,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:37:25Z","updated":"2017-08-07T04:37:25Z","lastEventDate":"2017-08-07T04:37:25Z"},{"id":22733,"type":"PATENT","title":"Citing Univ Dundee publications","description":"Patent documents citing scholarly work of Univ Dundee","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10319,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:44:56Z","updated":"2017-08-07T04:44:56Z","lastEventDate":"2017-08-07T04:44:56Z"},{"id":22734,"type":"PATENT","title":"Citing WIS publications","description":"Patent documents citing scholarly work of WIS","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22444,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:45:06Z","updated":"2017-08-07T04:45:06Z","lastEventDate":"2017-08-07T04:45:06Z"},{"id":22768,"type":"PATENT","title":"Citing Boston Univ publications","description":"Patent documents citing scholarly work of Boston Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":26250,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:56:41Z","updated":"2017-08-07T04:56:41Z","lastEventDate":"2017-08-07T04:56:41Z"},{"id":22787,"type":"PATENT","title":"Citing Univ Glasgow publications","description":"Patent documents citing scholarly work of Univ Glasgow","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17988,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:04:47Z","updated":"2017-08-07T05:04:47Z","lastEventDate":"2017-08-07T05:04:47Z"},{"id":22798,"type":"PATENT","title":"Citing Univ Edinburgh publications","description":"Patent documents citing scholarly work of Univ Edinburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21541,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:07Z","updated":"2017-08-07T05:09:07Z","lastEventDate":"2017-08-07T05:09:07Z"},{"id":22810,"type":"PATENT","title":"Citing Nth Carolina State Univ publications","description":"Patent documents citing scholarly work of Nth Carolina State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17064,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:25Z","updated":"2017-08-07T05:17:25Z","lastEventDate":"2017-08-07T05:17:25Z"},{"id":22811,"type":"PATENT","title":"Citing Univ Pennsylvania publications","description":"Patent documents citing scholarly work of Univ Pennsylvania","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":65126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:40Z","updated":"2017-08-07T05:17:40Z","lastEventDate":"2017-08-07T05:17:40Z"},{"id":22830,"type":"PATENT","title":"Citing Univ Pittsburgh publications","description":"Patent documents citing scholarly work of Univ Pittsburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39162,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:24:02Z","updated":"2017-08-07T05:24:02Z","lastEventDate":"2017-08-07T05:24:02Z"},{"id":22844,"type":"PATENT","title":"Citing Northwestern Univ publications","description":"Patent documents citing scholarly work of Northwestern Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":37711,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:29:24Z","updated":"2017-08-07T05:29:24Z","lastEventDate":"2017-08-07T05:29:24Z"},{"id":22855,"type":"PATENT","title":"Citing University College London (UCL) publications","description":"Patent documents citing scholarly work of University College London (UCL)","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:34:28Z","updated":"2017-08-07T05:34:28Z","lastEventDate":"2017-08-07T05:34:28Z"},{"id":22859,"type":"PATENT","title":"Citing Harvard Univ publications","description":"Patent documents citing scholarly work of Harvard Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":175224,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:37:44Z","updated":"2017-08-07T05:37:44Z","lastEventDate":"2017-08-07T05:37:44Z"},{"id":22864,"type":"PATENT","title":"Citing Ohio State Univ publications","description":"Patent documents citing scholarly work of Ohio State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":31507,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:42:04Z","updated":"2017-08-07T05:42:04Z","lastEventDate":"2017-08-07T05:42:04Z"},{"id":22878,"type":"PATENT","title":"Citing Univ London publications","description":"Patent documents citing scholarly work of Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":96093,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:35Z","updated":"2017-08-07T05:47:35Z","lastEventDate":"2017-08-07T05:47:35Z"},{"id":22887,"type":"PATENT","title":"Citing Tel Aviv Univ publications","description":"Patent documents citing scholarly work of Tel Aviv Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":20462,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:53:07Z","updated":"2017-08-07T05:53:07Z","lastEventDate":"2017-08-07T05:53:07Z"},{"id":22899,"type":"PATENT","title":"Citing Univ Rochester publications","description":"Patent documents citing scholarly work of Univ Rochester","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24884,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:06Z","updated":"2017-08-07T05:56:06Z","lastEventDate":"2017-08-07T05:56:06Z"},{"id":22901,"type":"PATENT","title":"Citing Johns Hopkins Univ publications","description":"Patent documents citing scholarly work of Johns Hopkins Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":76487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:37Z","updated":"2017-08-07T05:56:37Z","lastEventDate":"2017-08-07T05:56:37Z"},{"id":22907,"type":"PATENT","title":"Citing TUM publications","description":"Patent documents citing scholarly work of TUM","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22072,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:37Z","updated":"2017-08-07T05:59:37Z","lastEventDate":"2017-08-07T05:59:37Z"},{"id":23046,"type":"PATENT","title":"Citing Murdoch Childrens Research Institute publications","description":"Patent documents citing scholarly work of Murdoch Childrens Research Institute","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1558,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:23:26Z","updated":"2017-08-15T06:23:26Z","lastEventDate":"2017-08-15T06:23:26Z"},{"id":27083,"type":"PATENT","title":"Patents citing scholarly work funded by Wellcome Trust","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":45204,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2018-01-23T03:10:18Z","updated":"2018-01-23T03:17:28Z","lastEventDate":"2018-01-23T03:17:28Z"},{"id":185688,"type":"PATENT","title":"Food Safety","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":379426745,"username":"guzmanbarcenas","firstName":"","lastName":"","created":"2020-11-27T23:02:26.000Z","displayName":"guzmanbarcenas","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2020-11-27T23:38:28Z","updated":"2020-11-27T23:40:39Z","lastEventDate":"2020-11-27T23:40:39Z"},{"id":185689,"type":"PATENT","title":"Food Safety and Management Systems","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":379426745,"username":"guzmanbarcenas","firstName":"","lastName":"","created":"2020-11-27T23:02:26.000Z","displayName":"guzmanbarcenas","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2020-11-27T23:43:53Z","updated":"2020-11-27T23:45:31Z","lastEventDate":"2020-11-27T23:45:31Z"},{"id":187329,"type":"PATENT","title":"Diabetes supplement","description":"diabetes AND ( ( honey OR kelulut ) AND ( ( xanthone OR mangosteen ) OR supplement* ) )","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15115,"tags":[],"user":{"id":345934283,"username":"wma","firstName":"","lastName":"","created":"2020-02-18T04:50:26.000Z","displayName":"wma","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2021-01-20T04:34:44Z","updated":"2024-03-28T02:55:20Z","lastEventDate":"2024-03-28T02:55:20Z"}],"notes":[],"inventorships":[],"privateCollections":[],"publicCollections":[{"id":22718,"type":"PATENT","title":"Citing Vanderbilt Univ publications","description":"Patent documents citing scholarly work of Vanderbilt Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27696,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:37:25Z","updated":"2017-08-07T04:37:25Z","lastEventDate":"2017-08-07T04:37:25Z"},{"id":22733,"type":"PATENT","title":"Citing Univ Dundee publications","description":"Patent documents citing scholarly work of Univ Dundee","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10319,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:44:56Z","updated":"2017-08-07T04:44:56Z","lastEventDate":"2017-08-07T04:44:56Z"},{"id":22734,"type":"PATENT","title":"Citing WIS publications","description":"Patent documents citing scholarly work of WIS","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22444,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:45:06Z","updated":"2017-08-07T04:45:06Z","lastEventDate":"2017-08-07T04:45:06Z"},{"id":22768,"type":"PATENT","title":"Citing Boston Univ publications","description":"Patent documents citing scholarly work of Boston Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":26250,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T04:56:41Z","updated":"2017-08-07T04:56:41Z","lastEventDate":"2017-08-07T04:56:41Z"},{"id":22787,"type":"PATENT","title":"Citing Univ Glasgow publications","description":"Patent documents citing scholarly work of Univ Glasgow","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17988,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:04:47Z","updated":"2017-08-07T05:04:47Z","lastEventDate":"2017-08-07T05:04:47Z"},{"id":22798,"type":"PATENT","title":"Citing Univ Edinburgh publications","description":"Patent documents citing scholarly work of Univ Edinburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":21541,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:09:07Z","updated":"2017-08-07T05:09:07Z","lastEventDate":"2017-08-07T05:09:07Z"},{"id":22810,"type":"PATENT","title":"Citing Nth Carolina State Univ publications","description":"Patent documents citing scholarly work of Nth Carolina State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":17064,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:25Z","updated":"2017-08-07T05:17:25Z","lastEventDate":"2017-08-07T05:17:25Z"},{"id":22811,"type":"PATENT","title":"Citing Univ Pennsylvania publications","description":"Patent documents citing scholarly work of Univ Pennsylvania","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":65126,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:17:40Z","updated":"2017-08-07T05:17:40Z","lastEventDate":"2017-08-07T05:17:40Z"},{"id":22830,"type":"PATENT","title":"Citing Univ Pittsburgh publications","description":"Patent documents citing scholarly work of Univ Pittsburgh","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":39162,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:24:02Z","updated":"2017-08-07T05:24:02Z","lastEventDate":"2017-08-07T05:24:02Z"},{"id":22844,"type":"PATENT","title":"Citing Northwestern Univ publications","description":"Patent documents citing scholarly work of Northwestern Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":37711,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:29:24Z","updated":"2017-08-07T05:29:24Z","lastEventDate":"2017-08-07T05:29:24Z"},{"id":22855,"type":"PATENT","title":"Citing University College London (UCL) publications","description":"Patent documents citing scholarly work of University College London (UCL)","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":53487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:34:28Z","updated":"2017-08-07T05:34:28Z","lastEventDate":"2017-08-07T05:34:28Z"},{"id":22859,"type":"PATENT","title":"Citing Harvard Univ publications","description":"Patent documents citing scholarly work of Harvard Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":175224,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:37:44Z","updated":"2017-08-07T05:37:44Z","lastEventDate":"2017-08-07T05:37:44Z"},{"id":22864,"type":"PATENT","title":"Citing Ohio State Univ publications","description":"Patent documents citing scholarly work of Ohio State Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":31507,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:42:04Z","updated":"2017-08-07T05:42:04Z","lastEventDate":"2017-08-07T05:42:04Z"},{"id":22878,"type":"PATENT","title":"Citing Univ London publications","description":"Patent documents citing scholarly work of Univ London","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":96093,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:47:35Z","updated":"2017-08-07T05:47:35Z","lastEventDate":"2017-08-07T05:47:35Z"},{"id":22887,"type":"PATENT","title":"Citing Tel Aviv Univ publications","description":"Patent documents citing scholarly work of Tel Aviv Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":20462,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:53:07Z","updated":"2017-08-07T05:53:07Z","lastEventDate":"2017-08-07T05:53:07Z"},{"id":22899,"type":"PATENT","title":"Citing Univ Rochester publications","description":"Patent documents citing scholarly work of Univ Rochester","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24884,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:06Z","updated":"2017-08-07T05:56:06Z","lastEventDate":"2017-08-07T05:56:06Z"},{"id":22901,"type":"PATENT","title":"Citing Johns Hopkins Univ publications","description":"Patent documents citing scholarly work of Johns Hopkins Univ","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":76487,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:56:37Z","updated":"2017-08-07T05:56:37Z","lastEventDate":"2017-08-07T05:56:37Z"},{"id":22907,"type":"PATENT","title":"Citing TUM publications","description":"Patent documents citing scholarly work of TUM","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":22072,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-07T05:59:37Z","updated":"2017-08-07T05:59:37Z","lastEventDate":"2017-08-07T05:59:37Z"},{"id":23046,"type":"PATENT","title":"Citing Murdoch Childrens Research Institute publications","description":"Patent documents citing scholarly work of Murdoch Childrens Research Institute","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":1558,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2017-08-15T06:23:26Z","updated":"2017-08-15T06:23:26Z","lastEventDate":"2017-08-15T06:23:26Z"},{"id":27083,"type":"PATENT","title":"Patents citing scholarly work funded by Wellcome Trust","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":45204,"tags":[],"user":{"id":233682368,"username":"tech","firstName":"The Lens","lastName":"Team","created":"2017-08-06T20:11:49.000Z","displayName":"The Lens Team","profilePictureKey":"lens/users/15eac2a0-031d-4923-92cb-a162e1cb2bbb/profile-picture","preferences":"{\"beta\":true}","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2018-01-23T03:10:18Z","updated":"2018-01-23T03:17:28Z","lastEventDate":"2018-01-23T03:17:28Z"},{"id":185688,"type":"PATENT","title":"Food Safety","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":379426745,"username":"guzmanbarcenas","firstName":"","lastName":"","created":"2020-11-27T23:02:26.000Z","displayName":"guzmanbarcenas","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":false,"savedQueries":[],"created":"2020-11-27T23:38:28Z","updated":"2020-11-27T23:40:39Z","lastEventDate":"2020-11-27T23:40:39Z"},{"id":185689,"type":"PATENT","title":"Food Safety and Management Systems","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":50000,"tags":[],"user":{"id":379426745,"username":"guzmanbarcenas","firstName":"","lastName":"","created":"2020-11-27T23:02:26.000Z","displayName":"guzmanbarcenas","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2020-11-27T23:43:53Z","updated":"2020-11-27T23:45:31Z","lastEventDate":"2020-11-27T23:45:31Z"},{"id":187329,"type":"PATENT","title":"Diabetes supplement","description":"diabetes AND ( ( honey OR kelulut ) AND ( ( xanthone OR mangosteen ) OR supplement* ) )","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":15115,"tags":[],"user":{"id":345934283,"username":"wma","firstName":"","lastName":"","created":"2020-02-18T04:50:26.000Z","displayName":"wma","accountType":"PERSONAL","isOauthOnly":false},"notes":[],"sharedType":"PUBLISHED","hasLinkedSavedQueries":true,"savedQueries":[],"created":"2021-01-20T04:34:44Z","updated":"2024-03-28T02:55:20Z","lastEventDate":"2024-03-28T02:55:20Z"}],"privateNotes":[],"landscapeCollections":[],"landscapeNotes":[]},"document":{"record_lens_id":"120-954-513-287-333","lens_id":["120-954-513-287-333","189-770-061-013-194"],"doc_key":"US_8796333_B2_20140805","created":"2016-01-15T08:33:43.159","docdb_id":420574894,"lens_internal":{"earliest_lens_id_created_time":"2016-01-15T08:33:43.159","last_modified":"2024-03-25T23:52:56.245","legacy_pub_key":"US_8796333_B2","has_doc_lang":true,"has_biblio_lang":true,"has_all_title_lang":true,"has_all_abstract_lang":true,"has_all_claims_lang":true,"has_description_lang":true},"jurisdiction":"US","doc_number":"8796333","kind":"B2","date_published":"2014-08-05","year_published":2014,"ids":["US_8796333_B2","120-954-513-287-333","189-770-061-013-194","US_8796333_B2_20140805","US","8796333","B2","US8796333B2","US8796333","8796333B2"],"lang":"en","publication_type":"GRANTED_PATENT","application_reference":{"jurisdiction":"US","doc_number":"201213347750","kind":"A","date":"2012-01-11"},"priority_claim":[{"jurisdiction":"US","doc_number":"201213347750","kind":"A","date":"2012-01-11"},{"jurisdiction":"US","doc_number":"64197806","kind":"A","date":"2006-12-19"},{"jurisdiction":"US","doc_number":"75225305","kind":"P","date":"2005-12-19"}],"priority_claim.source":"DOCDB","earliest_priority_claim_date":"2005-12-19","title":{"en":[{"text":"Method of using β-hydroxy-β-methylbutyrate to treat a condition","lang":"en","source":"DOCDB","data_format":"DOCDBA"}]},"title_lang":["en"],"has_title":true,"applicant":[{"name":"THOMAS DEBRA L","residence":"US","sequence":1,"app_type":"applicant"},{"name":"MUKERJI PRADIP","residence":"US","sequence":2,"app_type":"applicant"},{"name":"ABBOTT LAB","residence":"US","sequence":3,"app_type":"applicant"}],"applicant_count":3,"has_applicant":true,"inventor":[{"name":"THOMAS DEBRA L","residence":"US","sequence":1},{"name":"MUKERJI PRADIP","residence":"US","sequence":2}],"inventor_count":2,"has_inventor":true,"agent":[{"name":"Calfee, Halter & Griswold LLP","sequence":1}],"agent_count":1,"has_agent":true,"owner":[{"name":"ABBOTT LABORATORIES","address":"100 ABBOTT PARK ROAD, ABBOTT PARK, ILLINOIS, 60064","sequence":2,"recorded_date":"2012-04-10","execution_date":"2012-03-22","is_current_owner":true}],"owner_count":1,"owner_all":[{"name":"ABBOTT LABORATORIES","address":"100 ABBOTT PARK ROAD, ABBOTT PARK, ILLINOIS, 60064","sequence":2,"recorded_date":"2012-04-10","execution_date":"2012-03-22","is_current_owner":true}],"owner_all_count":1,"has_owner":true,"primary_examiner":{"name":"Savitha Rao","department":"1621"},"assistant_examiner":{"name":"Gregg Polansky"},"has_examiner":true,"class_ipcr":[{"symbol":"A23L29/206","version_indicator":"2016-01-01","class_value":"I","action_date":"2019-10-14","class_status":"R","class_data_source":"M","generating_office":"EP","sequence":1},{"symbol":"A61K31/191","version_indicator":"2006-01-01","class_symbol_position":"F","class_value":"I","action_date":"2014-08-05","class_status":"B","class_data_source":"H","generating_office":"US","sequence":2},{"symbol":"A23L33/00","version_indicator":"2016-01-01","class_value":"I","action_date":"2019-10-14","class_status":"R","class_data_source":"M","generating_office":"EP","sequence":3},{"symbol":"A23L33/15","version_indicator":"2016-01-01","class_value":"I","action_date":"2019-10-14","class_status":"R","class_data_source":"M","generating_office":"EP","sequence":4},{"symbol":"A61K31/19","version_indicator":"2006-01-01","class_symbol_position":"L","class_value":"I","action_date":"2014-08-05","class_status":"B","class_data_source":"H","generating_office":"US","sequence":5}],"class_ipcr.first_symbol":"A61K31/191","class_ipcr.later_symbol":["A23L29/206","A23L33/00","A23L33/15","A61K31/19"],"class_ipcr.inv_symbol":["A23L29/206","A61K31/191","A23L33/00","A23L33/15","A61K31/19"],"class_ipcr.add_symbol":[],"class_ipcr.source":"DOCDB","class_cpc":[{"symbol":"A23L33/40","version_indicator":"2016-08-01","class_symbol_position":"L","class_value":"I","action_date":"2016-08-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":1},{"symbol":"A23L33/10","version_indicator":"2016-08-01","class_symbol_position":"L","class_value":"I","action_date":"2016-08-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":2},{"symbol":"A61K31/19","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":3},{"symbol":"A61P11/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-18","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":4},{"symbol":"A61P11/06","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-18","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":5},{"symbol":"A61P17/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-19","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":6},{"symbol":"A61P25/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-23","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":7},{"symbol":"A61P3/02","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-27","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":8},{"symbol":"A61P31/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-27","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":9},{"symbol":"A61P35/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-27","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":10},{"symbol":"A61P37/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-31","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":11},{"symbol":"A61P37/02","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-31","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":12},{"symbol":"A61P37/08","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-31","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":13},{"symbol":"A61P43/00","version_indicator":"2018-01-01","class_symbol_position":"L","class_value":"I","action_date":"2020-03-31","class_status":"B","class_data_source":"H","generating_office":"EP","sequence":14},{"symbol":"A23L33/40","version_indicator":"2016-08-01","class_symbol_position":"L","class_value":"I","action_date":"2019-10-11","class_status":"B","class_data_source":"H","generating_office":"US","sequence":15},{"symbol":"A23L33/10","version_indicator":"2016-08-01","class_symbol_position":"L","class_value":"I","action_date":"2019-10-11","class_status":"B","class_data_source":"H","generating_office":"US","sequence":16},{"symbol":"A61K31/19","version_indicator":"2013-01-01","class_symbol_position":"F","class_value":"I","action_date":"2013-01-01","class_status":"B","class_data_source":"H","generating_office":"US","sequence":17}],"class_cpc_cset":[],"class_cpc.first_symbol":"A61K31/19","class_cpc.later_symbol":["A23L33/40","A23L33/10","A61P11/00","A61P11/06","A61P17/00","A61P25/00","A61P3/02","A61P31/00","A61P35/00","A61P37/00","A61P37/02","A61P37/08","A61P43/00","A23L33/40","A23L33/10"],"class_cpc.inv_symbol":["A23L33/40","A23L33/10","A61K31/19","A61P11/00","A61P11/06","A61P17/00","A61P25/00","A61P3/02","A61P31/00","A61P35/00","A61P37/00","A61P37/02","A61P37/08","A61P43/00","A23L33/40","A23L33/10","A61K31/19"],"class_cpc.add_symbol":[],"class_cpc.source":"DOCDB","class_national":[{"symbol":"514/557","symbol_position":"F"},{"symbol":"514/826","symbol_position":"L"},{"symbol":"514/885","symbol_position":"L"}],"class_national.first_symbol":"514/557","class_national.later_symbol":["514/826","514/885"],"class_national.source":"DOCDB","reference_cited":[{"npl":{"num":1,"text":"MedicineNet, \"Cancer\", 2008, downloaded on Apr. 7, 2008 from http://www.medterms.com, 2 pages.","npl_type":"a","external_id":[],"lens_id":[],"sequence":1,"category":[],"us_category":[],"cited_phase":"SEA","rel_claims":[]}},{"patent":{"num":1,"document_id":{"jurisdiction":"US","doc_number":"3408210","kind":"A","date":"1968-10-29","name":"HEYMAN WILBERT A"},"lens_id":"102-524-864-834-850","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":1}},{"patent":{"num":2,"document_id":{"jurisdiction":"US","doc_number":"3542560","kind":"A","date":"1970-11-24","name":"TOMARELLI RUDOLPH M, et al"},"lens_id":"151-954-284-197-813","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":2}},{"patent":{"num":3,"document_id":{"jurisdiction":"US","doc_number":"4104290","kind":"A","date":"1978-08-01","name":"KOSLOWSKY LADISLAV"},"lens_id":"030-497-484-877-727","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":3}},{"patent":{"num":4,"document_id":{"jurisdiction":"US","doc_number":"4259358","kind":"A","date":"1981-03-31","name":"DUTHIE IAIN F"},"lens_id":"084-733-364-677-078","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":4}},{"patent":{"num":5,"document_id":{"jurisdiction":"US","doc_number":"4742081","kind":"A","date":"1988-05-03","name":"STRACHER ALFRED [US], et al"},"lens_id":"094-839-601-831-330","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":5}},{"patent":{"num":6,"document_id":{"jurisdiction":"US","doc_number":"4866040","kind":"A","date":"1989-09-12","name":"STRACHER ALFRED [US], et al"},"lens_id":"137-849-375-394-79X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":6}},{"patent":{"num":7,"document_id":{"jurisdiction":"US","doc_number":"4992470","kind":"A","date":"1991-02-12","name":"NISSEN STEVEN L [US]"},"lens_id":"023-580-827-311-578","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":7}},{"patent":{"num":8,"document_id":{"jurisdiction":"US","doc_number":"5000975","kind":"A","date":"1991-03-19","name":"TOMARELLI RUDOLPH M [US]"},"lens_id":"180-592-945-216-695","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":8}},{"patent":{"num":9,"document_id":{"jurisdiction":"US","doc_number":"5028440","kind":"A","date":"1991-07-02","name":"NISSEN STEVEN L [US]"},"lens_id":"144-508-882-441-472","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":9}},{"patent":{"num":10,"document_id":{"jurisdiction":"US","doc_number":"5087472","kind":"A","date":"1992-02-11","name":"NISSEN STEVEN L [US]"},"lens_id":"189-676-853-225-020","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":10}},{"patent":{"num":11,"document_id":{"jurisdiction":"US","doc_number":"5167957","kind":"A","date":"1992-12-01","name":"WEBB JR KENNETH E [US], et al"},"lens_id":"085-828-528-629-83X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":11}},{"patent":{"num":12,"document_id":{"jurisdiction":"US","doc_number":"5171442","kind":"A","date":"1992-12-15","name":"NAKSHBENDI GHASSAN F [US]"},"lens_id":"128-166-761-905-181","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":12}},{"patent":{"num":13,"document_id":{"jurisdiction":"US","doc_number":"5223285","kind":"A","date":"1993-06-29","name":"DEMICHELE STEPHEN J [US], et al"},"lens_id":"183-563-415-339-942","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":13}},{"patent":{"num":14,"document_id":{"jurisdiction":"US","doc_number":"5348979","kind":"A","date":"1994-09-20","name":"NISSEN STEVEN L [US], et al"},"lens_id":"119-872-005-739-781","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":14}},{"patent":{"num":15,"document_id":{"jurisdiction":"US","doc_number":"5360613","kind":"A","date":"1994-11-01","name":"NISSEN STEVEN L [US]"},"lens_id":"187-870-657-077-91X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":15}},{"patent":{"num":16,"document_id":{"jurisdiction":"US","doc_number":"5431928","kind":"A","date":"1995-07-11","name":"SAITO YASUHIRO [JP], et al"},"lens_id":"156-621-348-108-936","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":16}},{"patent":{"num":17,"document_id":{"jurisdiction":"US","doc_number":"5444054","kind":"A","date":"1995-08-22","name":"GARLEB KEITH A [US], et al"},"lens_id":"149-898-085-813-42X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":17}},{"patent":{"num":18,"document_id":{"jurisdiction":"US","doc_number":"5447732","kind":"A","date":"1995-09-05","name":"TANIMOTO HIROYUKI [JP], et al"},"lens_id":"123-668-485-662-459","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":18}},{"patent":{"num":19,"document_id":{"jurisdiction":"US","doc_number":"5457130","kind":"A","date":"1995-10-10","name":"TISDALE MICHAEL J [GB], et al"},"lens_id":"053-134-451-684-613","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":19}},{"patent":{"num":20,"document_id":{"jurisdiction":"US","doc_number":"5601860","kind":"A","date":"1997-02-11","name":"LIEN ERIC L [US], et al"},"lens_id":"171-718-479-111-152","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":20}},{"patent":{"num":21,"document_id":{"jurisdiction":"US","doc_number":"5641531","kind":"A","date":"1997-06-24","name":"LIEBRECHT JEFFERY WAYNE [US], et al"},"lens_id":"125-754-943-689-960","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":21}},{"patent":{"num":22,"document_id":{"jurisdiction":"US","doc_number":"5726146","kind":"A","date":"1998-03-10","name":"ALMADA ANTHONY L [US], et al"},"lens_id":"107-482-098-981-462","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":22}},{"patent":{"num":23,"document_id":{"jurisdiction":"US","doc_number":"5780451","kind":"A","date":"1998-07-14","name":"DEMICHELE STEPHEN JOSEPH [US], et al"},"lens_id":"184-638-050-229-483","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":23}},{"patent":{"num":24,"document_id":{"jurisdiction":"US","doc_number":"5834427","kind":"A","date":"1998-11-10","name":"HAN SANG KEE [KR], et al"},"lens_id":"111-147-038-350-665","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":24}},{"patent":{"num":25,"document_id":{"jurisdiction":"US","doc_number":"5976550","kind":"A","date":"1999-11-02","name":"ENGEL PETER H [US], et al"},"lens_id":"009-712-318-968-680","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":25}},{"patent":{"num":26,"document_id":{"jurisdiction":"US","doc_number":"6031000","kind":"A","date":"2000-02-29","name":"NISSEN STEVEN L [US], et al"},"lens_id":"026-988-156-049-852","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":26}},{"patent":{"num":27,"document_id":{"jurisdiction":"US","doc_number":"6060446","kind":"A","date":"2000-05-09","name":"ZALOGA GARY P [US], et al"},"lens_id":"115-122-832-511-387","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":27}},{"patent":{"num":28,"document_id":{"jurisdiction":"US","doc_number":"6080788","kind":"A","date":"2000-06-27","name":"SOLE MICHAEL J [CA], et al"},"lens_id":"194-389-085-204-743","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":28}},{"patent":{"num":29,"document_id":{"jurisdiction":"US","doc_number":"6103764","kind":"A","date":"2000-08-15","name":"NISSEN STEVEN L [US]"},"lens_id":"088-233-608-909-547","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":29}},{"patent":{"num":30,"document_id":{"jurisdiction":"US","doc_number":"6248909","kind":"B1","date":"2001-06-19","name":"AKIMOTO KENGO [JP], et al"},"lens_id":"189-948-606-799-699","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":30}},{"patent":{"num":31,"document_id":{"jurisdiction":"US","doc_number":"6291525","kind":"B1","date":"2001-09-18","name":"NISSEN STEVEN L [US]"},"lens_id":"147-245-485-886-66X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":31}},{"patent":{"num":32,"document_id":{"jurisdiction":"US","doc_number":"6294206","kind":"B1","date":"2001-09-25","name":"BARRETT-REIS BRIDGET [US], et al"},"lens_id":"050-748-326-102-917","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":32}},{"patent":{"num":33,"document_id":{"jurisdiction":"US","doc_number":"6340491","kind":"B1","date":"2002-01-22","name":"CAIN FREDERICK WILLIAM [NL], et al"},"lens_id":"096-506-745-958-83X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":33}},{"patent":{"num":34,"document_id":{"jurisdiction":"US","doc_number":"6420342","kind":"B1","date":"2002-07-16","name":"HAGEMAN ROBERT JOHAN JOSEPH [NL], et al"},"lens_id":"029-474-547-776-046","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":34}},{"patent":{"num":35,"document_id":{"jurisdiction":"US","doc_number":"6468987","kind":"B1","date":"2002-10-22","name":"DEMICHELE STEPHEN JOSEPH [US], et al"},"lens_id":"139-130-477-652-249","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":35}},{"patent":{"num":36,"document_id":{"jurisdiction":"US","doc_number":"6475539","kind":"B1","date":"2002-11-05","name":"DEWILLE NORMANELLA T [US], et al"},"lens_id":"122-402-007-028-782","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":36}},{"patent":{"num":37,"document_id":{"jurisdiction":"US","doc_number":"6521591","kind":"B1","date":"2003-02-18","name":"SMEETS RUDOLF LEONARDUS LODEWI [NL], et al"},"lens_id":"099-008-395-744-803","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":37}},{"patent":{"num":38,"document_id":{"jurisdiction":"US","doc_number":"6596767","kind":"B2","date":"2003-07-22","name":"MASOR MARC L [US], et al"},"lens_id":"185-447-130-959-827","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":38}},{"patent":{"num":39,"document_id":{"jurisdiction":"US","doc_number":"6620427","kind":"B2","date":"2003-09-16","name":"LASEKAN JOHN B [US], et al"},"lens_id":"148-481-066-667-287","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":39}},{"patent":{"num":40,"document_id":{"jurisdiction":"US","doc_number":"6660258","kind":"B1","date":"2003-12-09","name":"TOVEY MICHAEL GERARD [FR]"},"lens_id":"076-271-927-250-745","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":40}},{"patent":{"num":41,"document_id":{"jurisdiction":"US","doc_number":"6749881","kind":"B2","date":"2004-06-15","name":"KATAOKA KIYOSHI [JP], et al"},"lens_id":"057-596-864-193-259","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":41}},{"patent":{"num":42,"document_id":{"jurisdiction":"US","doc_number":"7332178","kind":"B2","date":"2008-02-19","name":"BYARD JULIA A [US], et al"},"lens_id":"148-001-770-944-414","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":42}},{"patent":{"num":43,"document_id":{"jurisdiction":"US","doc_number":"7419596","kind":"B2","date":"2008-09-02","name":"DUEPPEN DANIEL G [US], et al"},"lens_id":"188-804-932-153-544","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":43}},{"patent":{"num":44,"document_id":{"jurisdiction":"US","doc_number":"7435442","kind":"B2","date":"2008-10-14","name":"SERVOTTE YVES [BE]"},"lens_id":"189-663-784-510-270","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":44}},{"patent":{"num":45,"document_id":{"jurisdiction":"US","doc_number":"7445807","kind":"B2","date":"2008-11-04","name":"LOCKWOOD CHRISTOPHER [US]"},"lens_id":"037-940-252-174-73X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":45}},{"patent":{"num":46,"document_id":{"jurisdiction":"US","doc_number":"7498026","kind":"B2","date":"2009-03-03","name":"DAHLQVIST ANDERS [SE], et al"},"lens_id":"056-306-414-620-28X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":46}},{"patent":{"num":47,"document_id":{"jurisdiction":"US","doc_number":"7517850","kind":"B2","date":"2009-04-14","name":"HOLT CARL [GB]"},"lens_id":"166-031-370-988-418","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":47}},{"patent":{"num":48,"document_id":{"jurisdiction":"US","doc_number":"7696241","kind":"B2","date":"2010-04-13","name":"LI JAMES J [US], et al"},"lens_id":"111-196-474-956-963","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":48}},{"patent":{"num":49,"document_id":{"jurisdiction":"US","doc_number":"7795204","kind":"B2","date":"2010-09-14","name":"GARDINER PAUL T [CA], et al"},"lens_id":"063-927-740-131-073","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":49}},{"patent":{"num":50,"document_id":{"jurisdiction":"US","doc_number":"7825084","kind":"B2","date":"2010-11-02","name":"HARRIS ROGER [GB], et al"},"lens_id":"142-233-889-007-887","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":50}},{"patent":{"num":51,"document_id":{"jurisdiction":"US","doc_number":"8217077","kind":"B2","date":"2012-07-10","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"149-284-567-045-164","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":51}},{"patent":{"num":52,"document_id":{"jurisdiction":"US","doc_number":"8609725","kind":"B2","date":"2013-12-17","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"136-770-882-460-44X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":52}},{"patent":{"num":53,"document_id":{"jurisdiction":"US","doc_number":"2001008641","kind":"A1","date":"2001-07-19","name":"KROTZER R DOUGLAS [US]"},"lens_id":"041-459-289-775-049","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":53}},{"patent":{"num":54,"document_id":{"jurisdiction":"US","doc_number":"2002035965","kind":"A1","date":"2002-03-28","name":"UNI ZEHAVA [IL], et al"},"lens_id":"020-665-334-625-396","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":54}},{"patent":{"num":55,"document_id":{"jurisdiction":"US","doc_number":"2003092609","kind":"A1","date":"2003-05-15","name":"LARSEN BJARNE DUE [DK], et al"},"lens_id":"140-409-303-816-374","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":55}},{"patent":{"num":56,"document_id":{"jurisdiction":"US","doc_number":"2003165604","kind":"A1","date":"2003-09-04","name":"TSUBAKI KAZUFUMI [JP], et al"},"lens_id":"016-459-442-845-482","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":56}},{"patent":{"num":57,"document_id":{"jurisdiction":"US","doc_number":"2003176514","kind":"A1","date":"2003-09-18","name":"FUHRMANN MARTIN [DE], et al"},"lens_id":"111-779-988-219-885","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":57}},{"patent":{"num":58,"document_id":{"jurisdiction":"US","doc_number":"2003203070","kind":"A1","date":"2003-10-30","name":"LIN PETER YAU TAK [US], et al"},"lens_id":"052-304-648-171-654","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":58}},{"patent":{"num":59,"document_id":{"jurisdiction":"US","doc_number":"2004013787","kind":"A1","date":"2004-01-22","name":"THEUER RICHARD C [US]"},"lens_id":"166-051-237-215-393","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":59}},{"patent":{"num":60,"document_id":{"jurisdiction":"US","doc_number":"2004048925","kind":"A1","date":"2004-03-11","name":"WILEY DAVID B [US], et al"},"lens_id":"189-574-785-346-340","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":60}},{"patent":{"num":61,"document_id":{"jurisdiction":"US","doc_number":"2004071825","kind":"A1","date":"2004-04-15","name":"LOCKWOOD CHRISTOPHER [US]"},"lens_id":"052-704-334-060-161","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":61}},{"patent":{"num":62,"document_id":{"jurisdiction":"US","doc_number":"2004106678","kind":"A1","date":"2004-06-03","name":"DOBBINS THOMAS A [US], et al"},"lens_id":"040-424-701-848-62X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":62}},{"patent":{"num":63,"document_id":{"jurisdiction":"US","doc_number":"2004122210","kind":"A1","date":"2004-06-24","name":"THIM LARS [DK], et al"},"lens_id":"156-088-187-733-913","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":63}},{"patent":{"num":64,"document_id":{"jurisdiction":"US","doc_number":"2004202770","kind":"A1","date":"2004-10-14","name":"CAIN FREDERICK WILLIAM [NL], et al"},"lens_id":"088-949-206-074-579","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":64}},{"patent":{"num":65,"document_id":{"jurisdiction":"US","doc_number":"2004237466","kind":"A1","date":"2004-12-02","name":"GROSSMANN HOLGER [DE], et al"},"lens_id":"182-178-572-186-807","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":65}},{"patent":{"num":66,"document_id":{"jurisdiction":"US","doc_number":"2004248771","kind":"A1","date":"2004-12-09","name":"RAGGI GIUSEPPE [CH]"},"lens_id":"029-187-777-288-951","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":66}},{"patent":{"num":67,"document_id":{"jurisdiction":"US","doc_number":"2005075280","kind":"A1","date":"2005-04-07","name":"LARSEN BJARNE DUE [DK], et al"},"lens_id":"173-722-665-512-325","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":67}},{"patent":{"num":68,"document_id":{"jurisdiction":"US","doc_number":"2005106219","kind":"A1","date":"2005-05-19","name":"BORTLIK KARLHEINZ [CH], et al"},"lens_id":"100-119-491-588-543","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":68}},{"patent":{"num":69,"document_id":{"jurisdiction":"US","doc_number":"2005215640","kind":"A1","date":"2005-09-29","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"123-233-831-799-085","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":69}},{"patent":{"num":70,"document_id":{"jurisdiction":"US","doc_number":"2005249650","kind":"A1","date":"2005-11-10","name":"JOHANNES DAMHUIS EDUARD H [BE], et al"},"lens_id":"162-147-700-694-180","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":70}},{"patent":{"num":71,"document_id":{"jurisdiction":"US","doc_number":"2006193961","kind":"A1","date":"2006-08-31","name":"SHASTRI SIDDHARTH [US], et al"},"lens_id":"015-691-135-140-298","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":71}},{"patent":{"num":72,"document_id":{"jurisdiction":"US","doc_number":"2006204632","kind":"A1","date":"2006-09-14","name":"BARRETT-REIS BRIDGET [US], et al"},"lens_id":"119-520-130-672-783","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":72}},{"patent":{"num":73,"document_id":{"jurisdiction":"US","doc_number":"2006286210","kind":"A1","date":"2006-12-21","name":"RANGAVAJLA NAGENDRA [US], et al"},"lens_id":"050-556-186-129-168","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":73}},{"patent":{"num":74,"document_id":{"jurisdiction":"US","doc_number":"2006293220","kind":"A1","date":"2006-12-28","name":"HOLT CARL [GB]"},"lens_id":"119-493-734-521-002","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":74}},{"patent":{"num":75,"document_id":{"jurisdiction":"US","doc_number":"2007093553","kind":"A1","date":"2007-04-26","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"094-248-149-410-593","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":75}},{"patent":{"num":76,"document_id":{"jurisdiction":"US","doc_number":"2007125785","kind":"A1","date":"2007-06-07","name":"ROBINSON CLAYTON L [US], et al"},"lens_id":"119-851-853-984-488","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":76}},{"patent":{"num":77,"document_id":{"jurisdiction":"US","doc_number":"2007142469","kind":"A1","date":"2007-06-21","name":"THOMAS DEBRA L [US], et al"},"lens_id":"029-487-766-828-603","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":77}},{"patent":{"num":78,"document_id":{"jurisdiction":"US","doc_number":"2008031860","kind":"A1","date":"2008-02-07","name":"HAGEMAN ROBERT JOHAN JOSEPH [NL]"},"lens_id":"060-963-379-805-944","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":78}},{"patent":{"num":79,"document_id":{"jurisdiction":"US","doc_number":"2008058415","kind":"A1","date":"2008-03-06","name":"SHULMAN AVIDOR [IL], et al"},"lens_id":"008-669-133-461-712","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":79}},{"patent":{"num":80,"document_id":{"jurisdiction":"US","doc_number":"2008119552","kind":"A1","date":"2008-05-22","name":"NAVARRO FELIPE [US]"},"lens_id":"032-203-966-082-659","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":80}},{"patent":{"num":81,"document_id":{"jurisdiction":"US","doc_number":"2008193624","kind":"A1","date":"2008-08-14","name":"SHULMAN AVIDOR [IL], et al"},"lens_id":"164-052-754-428-92X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":81}},{"patent":{"num":82,"document_id":{"jurisdiction":"US","doc_number":"2008194407","kind":"A1","date":"2008-08-14","name":"ASHMEAD H DEWAYNE [US], et al"},"lens_id":"156-548-957-520-004","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":82}},{"patent":{"num":83,"document_id":{"jurisdiction":"US","doc_number":"2008254153","kind":"A1","date":"2008-10-16","name":"WANG JUNKUAN [CH], et al"},"lens_id":"181-334-547-033-329","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":83}},{"patent":{"num":84,"document_id":{"jurisdiction":"US","doc_number":"2008260923","kind":"A1","date":"2008-10-23","name":"KRATKY ZDENEK [US], et al"},"lens_id":"003-102-274-522-153","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":84}},{"patent":{"num":85,"document_id":{"jurisdiction":"US","doc_number":"2008274230","kind":"A1","date":"2008-11-06","name":"JOHNS PAUL W [US], et al"},"lens_id":"193-265-632-582-735","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":85}},{"patent":{"num":86,"document_id":{"jurisdiction":"US","doc_number":"2008305531","kind":"A1","date":"2008-12-11","name":"LAM DAVID [US], et al"},"lens_id":"067-976-740-056-110","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":86}},{"patent":{"num":87,"document_id":{"jurisdiction":"US","doc_number":"2008317886","kind":"A1","date":"2008-12-25","name":"SPARKMAN DENNIS R [US]"},"lens_id":"005-896-331-127-564","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":87}},{"patent":{"num":88,"document_id":{"jurisdiction":"US","doc_number":"2009087540","kind":"A1","date":"2009-04-02","name":"HASCHKE FERDINAND [CH], et al"},"lens_id":"057-866-139-075-521","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":88}},{"patent":{"num":89,"document_id":{"jurisdiction":"US","doc_number":"2009110674","kind":"A1","date":"2009-04-30","name":"LOIZOU NICOS C [US]"},"lens_id":"074-660-062-023-653","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":89}},{"patent":{"num":90,"document_id":{"jurisdiction":"US","doc_number":"2009220637","kind":"A1","date":"2009-09-03","name":"ROESSLE CLAUDIA [CH]"},"lens_id":"187-530-983-370-782","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":90}},{"patent":{"num":91,"document_id":{"jurisdiction":"US","doc_number":"2009263367","kind":"A1","date":"2009-10-22","name":"FOLEY RYAN JASON [CA]"},"lens_id":"173-721-912-694-484","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":91}},{"patent":{"num":92,"document_id":{"jurisdiction":"US","doc_number":"2010179112","kind":"A1","date":"2010-07-15","name":"RATHMACHER JOHN [US], et al"},"lens_id":"092-481-057-850-143","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":92}},{"patent":{"num":93,"document_id":{"jurisdiction":"US","doc_number":"2011218244","kind":"A1","date":"2011-09-08","name":"KNELLER BRUCE W [US]"},"lens_id":"109-807-095-159-92X","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":93}},{"patent":{"num":94,"document_id":{"jurisdiction":"US","doc_number":"2011256301","kind":"A1","date":"2011-10-20","name":"KENSLER ANN M [US], et al"},"lens_id":"079-369-933-203-755","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":94}},{"patent":{"num":95,"document_id":{"jurisdiction":"US","doc_number":"2012141448","kind":"A1","date":"2012-06-07","name":"DE FERRA LORENZO [IT], et al"},"lens_id":"106-651-466-338-701","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":95}},{"patent":{"num":96,"document_id":{"jurisdiction":"US","doc_number":"2012177744","kind":"A1","date":"2012-07-12","name":"THOMAS DEBRA L [US], et al"},"lens_id":"135-729-541-076-684","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":96}},{"patent":{"num":97,"document_id":{"jurisdiction":"US","doc_number":"2012177752","kind":"A1","date":"2012-07-12","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"015-058-469-312-885","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":97}},{"patent":{"num":98,"document_id":{"jurisdiction":"US","doc_number":"2012178811","kind":"A1","date":"2012-07-12","name":"THOMAS DEBRA L [US], et al"},"lens_id":"144-965-630-942-389","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":98}},{"patent":{"num":99,"document_id":{"jurisdiction":"US","doc_number":"2012189714","kind":"A1","date":"2012-07-26","name":"BAXTER JEFFREY H [US], et al"},"lens_id":"024-778-601-618-016","category":[],"us_category":[],"cited_phase":"APP","rel_claims":[],"sequence":99}},{"npl":{"num":1,"text":"Office Action issued in U.S. Appl. No. 13/016,005, dated Jun. 1, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":100,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":2,"text":"Examiner's First Report in Australian Patent Application No. 2006331950, dated Apr. 19, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":101,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":3,"text":"Anonymous, \"Reload Dietary Supplements,\" Database GNPD (Online) Mintel, May 2010, XP002676291, available at www.gnpd.com.","npl_type":"a","xp_number":"002676291","external_id":[],"lens_id":[],"sequence":102,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":4,"text":"Charbonneau, \"Recent case histories of food product-metal container interactions using scanning electron microscopy-x-ray microanalysis,\" Scanning, vol. 19(7), pp. 512-518 (1997).","npl_type":"a","external_id":["9353869","10.1002/sca.4950190710"],"record_lens_id":"001-430-752-667-630","lens_id":["185-923-184-745-028","001-430-752-667-630","176-783-104-446-565"],"sequence":103,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":5,"text":"International Search Report and Written Opinion for International Application No. PCT/US2012/024817, dated Jun. 6, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":104,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":6,"text":"International Search Report and Written Opinion for International Application No. PCT/US2012/023767, dated Jun. 6, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":105,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":7,"text":"Montanari et al., \"Quality of Organic Coatings for Food Cans: Evaluation Techniques and Prospects of Improvement,\" Progress in Organic Coatings, vol. 29(1-4), pp. 159-165 (1996).","npl_type":"a","external_id":["10.1016/s0300-9440(96)00625-x"],"record_lens_id":"130-804-471-255-884","lens_id":["193-467-054-558-885","130-804-471-255-884"],"sequence":106,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":8,"text":"Final Office Action for U.S. Appl. No. 13/016,041, dated Jun. 8, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":107,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":9,"text":"English translation of Office Action issued in Chinese Patent Application No. 201110084963, dated Mar. 30, 2012.","npl_type":"a","external_id":[],"lens_id":[],"sequence":108,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":10,"text":"Office action issued in Chinese App. No. 200580009596.0, dated Jun. 28, 2010.","npl_type":"a","external_id":[],"lens_id":[],"sequence":109,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":11,"text":"Office action issued in Taiwan App. No. 094109357, dated Dec. 2, 2010.","npl_type":"a","external_id":[],"lens_id":[],"sequence":110,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":12,"text":"Oliver et al., \"Airway Smooth Muscle and Asthma,\" Allergology International, vol. 55, pp. 215-223 (2006).","npl_type":"a","external_id":["17075261","10.2332/allergolint.55.215"],"record_lens_id":"111-614-695-870-898","lens_id":["188-145-222-276-121","111-614-695-870-898","184-864-367-207-173"],"sequence":111,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":13,"text":"Ostaszewski et al., \"3-Hydroxy-3-Methylbutyrate (HMB) Fed in the Water Enhance Immune Response in Young Broilers,\" Abstract 96, . 25.","npl_type":"a","external_id":[],"lens_id":[],"sequence":112,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":14,"text":"Ostaszewski et al., \"The immunomodulating activity of dietary 3-hydroxy-3-methylbutyrate (HMB) in weaning pigs,\" J. Anim. Sci., vol. 81, Supplemental 1, p. 136 (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":113,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":15,"text":"Ostaszewski et al., \"The leucine metabolite 3-hydroxy-3-methylbutyrate (HMB) modifies protein turnover in muscles of laboratory rates and domestic chickens in vitro,\" J. Anim. Physiol. A. Anim. Nutr. 84, pp. 1-8 (2000).","npl_type":"a","external_id":["10.1046/j.1439-0396.2000.00272.x"],"record_lens_id":"034-956-350-207-07X","lens_id":["155-443-522-449-694","034-956-350-207-07X"],"sequence":114,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":16,"text":"Ostaszewski et al., \"The effect of the leucine metabolite 3-hydroxy 3-methylbutyrate (HMB) on muscle protein synthesis and protein breakdown in chick and rat muscle,\" Journal of Animal Science, vol. 74, Supplemental 1, p. 138 (1996).","npl_type":"a","external_id":[],"lens_id":[],"sequence":115,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":17,"text":"Ostaszewski et al., \"Dietary supplementation of 3-hydroxy-3-methylbutyrate improved catch-up growth in underfed lambs,\" Ann. Zootech , vol. 43, p. 308 (1994).","npl_type":"a","external_id":["10.1051/animres:19940375"],"record_lens_id":"103-849-835-696-817","lens_id":["193-195-718-087-128","103-849-835-696-817"],"sequence":116,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":18,"text":"Panton et al., \"Effect of b-hydroxy-b-methylbutyrate and resistance training on strength and functional ability in the elderly,\" Medicine & Science in Sports & Exercise, p. S194 (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":117,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":19,"text":"Panton et al., \"Nutritional supplementation of the leucine metabolite b-hydroxy-b-methylbutyrate (HMB) during resistance training,\" Nutrition, vol. 16, pp. 734-739 (2000).","npl_type":"a","external_id":["10978853","10.1016/s0899-9007(00)00376-2"],"record_lens_id":"051-807-095-085-526","lens_id":["179-702-793-241-080","051-807-095-085-526","185-646-601-624-014"],"sequence":118,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":20,"text":"Papet et al., \"The effect of a high dose of 3-hydroxy-3-methylbutyrate on protein metabolism in growing lambs,\" Br. J. Nutr., vol. 77, pp. 885-896 (1997).","npl_type":"a","external_id":["9227186","10.1079/bjn19970087"],"record_lens_id":"003-069-120-753-563","lens_id":["153-892-998-765-95X","003-069-120-753-563","048-891-298-618-579"],"sequence":119,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":21,"text":"Perkins et al., \"Good cop, bad cop: the different faces of NF-kB,\" Cell Death and Differentiation, vol. 13, pp. 759-772 (2006).","npl_type":"a","external_id":["10.1038/sj.cdd.4401838","16410803"],"record_lens_id":"006-070-391-218-893","lens_id":["148-668-298-658-099","006-070-391-218-893","046-537-942-938-107"],"sequence":120,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":22,"text":"Peterson et al., \"Enhancement of cellular and humoral immunity in young broilers by the dietary supplementation of b-hydroxy-b-methylbutyrate,\" Immunopharmacology and Immunotoxicity, vol. 21, No. 2, pp. 307-330 (1999).","npl_type":"a","external_id":["10319283","10.3109/08923979909052765"],"record_lens_id":"034-727-282-323-407","lens_id":["087-146-033-814-667","034-727-282-323-407","095-118-282-159-845"],"sequence":121,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":23,"text":"Peterson et al., \"In Vitro Exposure with B-Hydroxy-B-Methylbutyrate Enhances Chicken Macrophage Growth and Function,\" Vetrinary Immunology and Immunopathology, vol. 67, pp. 67-78 (1999).","npl_type":"a","external_id":["10.1016/s0165-2427(98)00211-6","9950355"],"record_lens_id":"054-874-114-681-059","lens_id":["133-448-902-783-963","054-874-114-681-059","120-318-984-788-209"],"sequence":122,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":24,"text":"Porter et al., \"Sustained NFAT Signaling Promotes a Th1-like Pattern of Gene Expression in Primary Murine CD4+ T Cells,\" Journal of Immunology, vol. 168, pp. 4936-4945 (2002).","npl_type":"a","external_id":["10.4049/jimmunol.168.10.4936","11994444"],"record_lens_id":"009-282-405-295-27X","lens_id":["128-050-063-401-360","009-282-405-295-27X","106-841-568-977-886"],"sequence":123,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":25,"text":"Rathbacher et al., \"Safety of a nutritional mixture of b-hydroxy-b-methylbutyrate (HMB), glutamine and arginine in healthy young adults and patients with AIDS,\" JPEN 23(1): S10 (1999).","npl_type":"a","external_id":[],"lens_id":[],"sequence":124,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":26,"text":"Rathmacher et al., \"The effect of the leucine metabolite b-hydroxy-b-methylbutyrate on lean body mass and muscle strength during prolonged bedrest,\" FASEB J., p. A909.","npl_type":"a","external_id":[],"lens_id":[],"sequence":125,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":27,"text":"Rathmacher et al., \"Supplementation with a combination of beta-hydroxy-beta-methylbutyrate (HMB), arginine, and glutamine is safe and could improve hematological parameters,\" Journal of Parenteral and Enternal Nutrition, vol. 28, No. 2, p. 65-75 (2004).","npl_type":"a","external_id":["15080599","10.1177/014860710402800265"],"record_lens_id":"087-755-177-106-786","lens_id":["179-173-443-049-67X","131-640-790-164-355","087-755-177-106-786"],"sequence":126,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":28,"text":"Sandberg et al., \"Effect of b-hydroxy-b-methylbutyrate on the physiological response to exercise and conditioning in horses,\" Journal of Animal Science, p. 198 (1997).","npl_type":"a","external_id":[],"lens_id":[],"sequence":127,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":29,"text":"Sandberg et al., \"The Effect of Intensive Training and b-hydroxy-b-methylbutyrate (HMB) on Muscle Glycogen concentration in the Horse,\" Journal of Animal Science, vol. 76, Supplemental 1, p. 175 (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":128,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":30,"text":"Siwicki et al., \"Immunomodulating effect of 3-hydroxy-3-methylbutyrate (HMB) on the nonspecific cellular and humaoral defense mechanisms in rainbow trout (Oncorhynchus nykiss),\" Journal of Animal Science, vol. 76, Supplemental 1, p. 137, (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":129,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":31,"text":"Siwicki et al., \"In Vitro Effects of 3-Hydroxy-3-methylbutyrate (HMB) on measures of immune function and immunocompetence in fish,\" Journal of Animal Science, vol. 76, Supplemental 1, p. 136 (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":130,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":32,"text":"Siwicki et al., \"Influence of 3-hydroxy-3-methylbutyrate on specific cellular immune response after in vitro and in vivo immunization with Yersinia ruckeri antifen,\" Journal of Animal Science, vol. 76, Supplemental 1, p. 136 (1998).","npl_type":"a","external_id":[],"lens_id":[],"sequence":131,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":33,"text":"Smith et al., \"Mechanisms of the attentuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate.\" Cancer Research, pp. 8731-8735 (2004).","npl_type":"a","external_id":["10.1158/0008-5472.can-04-1760","15574784"],"record_lens_id":"056-444-554-100-863","lens_id":["176-545-756-094-661","056-444-554-100-863","058-953-590-677-457"],"sequence":132,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":34,"text":"Talleyrand et al., \"Effect of feeding b-hydroxy-b-methylbutyrate on immune function in stressed calves,\" FASEB J, p. A951 (1994).","npl_type":"a","external_id":[],"lens_id":[],"sequence":133,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":35,"text":"Talleyrand et al., \"Uptake and output of the leucine metabolite b-hydroxy-b-methylbutyrate (HMB) across the legs of pigs,\" FASEB J., p. A71 (1993).","npl_type":"a","external_id":[],"lens_id":[],"sequence":134,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":36,"text":"Tisdale et al., \"Inhibition of Weight Loss by w-3 Fatty Acids in an Experimental Cachexia Model,\" Cancer Research, vol. 50, pp. 5002-5026 (1990).","npl_type":"a","external_id":["2379167"],"record_lens_id":"122-443-095-501-672","lens_id":["154-931-420-321-848","122-443-095-501-672"],"sequence":135,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":37,"text":"Van Koevering et al., \"Effect of b-hydroxy-b-methylbutyrate on the health and performance of shipping-stressed calves,\" The Oklahoma State Animal Science Research Report, pp. 312-316 (1993).","npl_type":"a","external_id":[],"lens_id":[],"sequence":136,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":38,"text":"Van Koevering et al., \"Oxidation of leucine and a-ketoisocaproate to b-hydroxy-b-methylbutyrate in vivo,\" American Journal of Physiology, pp. E27-E31 (1992).","npl_type":"a","external_id":["1733247","10.1152/ajpendo.1992.262.1.e27"],"record_lens_id":"066-524-547-832-268","lens_id":["134-606-101-630-69X","066-524-547-832-268","125-403-113-128-289"],"sequence":137,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":39,"text":"Vukovich et al., \"Body composition of 70-year-old adults responds to dietary beta-hydroxy beta-methylbutyrate similarly to that of young adults,\" Journal of Nutrition, vol. 131, No. 7, pp. 2049-2052 (2001).","npl_type":"a","external_id":["11435528","10.1093/jn/131.7.2049"],"record_lens_id":"039-005-353-293-186","lens_id":["086-652-617-483-588","039-005-353-293-186","044-467-317-018-811"],"sequence":138,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":40,"text":"Vukovich et al., \"Effect of beta-hydroxy beta -methylbutyrate on the onset of blood lactate accumulation and VO2 peak in endurance-trained cyclists,\" J. Strength & Conditioning Res., vol. 15, No. 4, pp. 491-497 (2001).","npl_type":"a","external_id":["11726262","10.1519/1533-4287(2001)015<0491:eohmot>2.0.co;2","10.1519/00124278-200111000-00015"],"record_lens_id":"003-316-067-645-269","lens_id":["159-295-741-832-523","003-316-067-645-269","044-388-263-081-35X","120-441-273-281-106","158-002-366-982-299"],"sequence":139,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":41,"text":"Vukovich et al., \"The effect of dietary b-hydroxy-b-methylbutyrate (HMB) on strength gains and body composition in older adults,\" FASEB J., p. A376 (1997).","npl_type":"a","external_id":[],"lens_id":[],"sequence":140,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":42,"text":"Williams et al., \"Effect of a specialized amino acid mixture on human collagen deposition,\" Annals of Surgery, vol. 236, No. 3, pp. 369-375 (2002).","npl_type":"a","external_id":["12192323","pmc1422590","10.1097/00000658-200209000-00013"],"record_lens_id":"038-852-585-136-068","lens_id":["141-489-668-480-665","038-852-585-136-068","163-997-058-193-473"],"sequence":141,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":43,"text":"Witte et al., \"Nutritional abnormalities contributing to cachexia in chronic illness,\" International Journal of Cardiology, vol. 85, pp. 23-31 (2002).","npl_type":"a","external_id":["10.1016/s0167-5273(02)00231-0","12163207"],"record_lens_id":"013-049-568-948-216","lens_id":["133-473-094-449-688","013-049-568-948-216","100-444-723-554-051"],"sequence":142,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":44,"text":"Zachwieja et al., \"Effect of the Leucine Metabolite b-hydroxy-b-methylbutyrate on muscle protein synthesis during prolonged bedrest,\" FASEB Abstracts, p. A1025 (1999).","npl_type":"a","external_id":[],"lens_id":[],"sequence":143,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":45,"text":"Zhang et al., \"Change in plasma b-hydroxy-b-methylbutyrate (HMB) by feeding leucine, a-ketiusicaoriate and isovaleric acid to pigs,\" FASEB J., p. A392 (1993).","npl_type":"a","external_id":[],"lens_id":[],"sequence":144,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":46,"text":"Examination Report for Vietnam Application No. 1-2006-01765, issued Aug. 18, 2011.","npl_type":"a","external_id":[],"lens_id":[],"sequence":145,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":47,"text":"Andela, et al., \"NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone,\" Clinical Orthopaedics and Related Research, vol. 415S, pp. S75-S85 (2003).","npl_type":"a","external_id":["10.1097/01.blo.0000093048.96273.aa","14600595"],"record_lens_id":"022-956-045-875-199","lens_id":["132-054-565-986-912","022-956-045-875-199","183-057-757-714-763"],"sequence":146,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":48,"text":"Andrews, et al. \"A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells,\" Nucleic Acids Res., vol. 19, No. 9, p. 2499 (1991).","npl_type":"a","external_id":["10.1093/nar/19.9.2499","2041787","pmc329467"],"record_lens_id":"079-431-666-862-792","lens_id":["129-274-811-406-175","079-431-666-862-792","150-377-584-993-850"],"sequence":147,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":49,"text":"Battaini, \"Protein kinase C isoforms as therapeutic targets in nervous systemdisease states,\" Pharmacological Research, vol. 44, No. 5, pp. 353-361 (2001).","npl_type":"a","external_id":["11712865","10.1006/phrs.2001.0893"],"record_lens_id":"072-441-152-691-628","lens_id":["093-656-664-513-868","072-441-152-691-628","097-316-579-410-033"],"sequence":148,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":50,"text":"Bibby et al., \"Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals,\" J. Natl. Cancer Inst., vol. 78, No. 3, pp. 539-546 (1987).","npl_type":"a","external_id":["3546909","10.1093/jnci/78.3.539"],"record_lens_id":"007-456-046-524-978","lens_id":["054-735-417-169-626","007-456-046-524-978","020-976-388-953-393","119-889-829-777-378"],"sequence":149,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":51,"text":"Carter, \"Protein Kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer,\" Current Drug Targets, vol. 12 , No. 2, pp. 163-183 (2000).","npl_type":"a","external_id":["10.2174/1389450003349317","11465069"],"record_lens_id":"056-152-310-488-473","lens_id":["075-005-509-411-480","056-152-310-488-473","124-256-214-133-315"],"sequence":150,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":52,"text":"Coffman et al.,\"Syntheses by Free-radical Reactions. V. A New Synthesis of Carboxylic Acids\", J. Am. Chem. Soc., vol. 80, pp. 2282-2887 (1958).","npl_type":"a","external_id":["10.1021/ja01544a072"],"record_lens_id":"046-105-088-514-524","lens_id":["095-200-017-561-211","046-105-088-514-524"],"sequence":151,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":53,"text":"Delfino, \"Hormonal Regulation of the NF-kappaB signaling pathway,\" Molecular and Cellular Endocrinology, vol. 157, Nos. 1-2, pp. 1-9 (1999).","npl_type":"a","external_id":["10.1016/s0303-7207(99)00127-6","10619392"],"record_lens_id":"061-105-932-711-755","lens_id":["092-312-591-989-623","061-105-932-711-755","162-873-599-760-126"],"sequence":152,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":54,"text":"Dentener et al., \"Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations,\" Thorax, vol. 56, No. 9, pp. 721-726 (2001).","npl_type":"a","external_id":["10.1136/thorax.56.9.721","11514694","pmc1746133"],"record_lens_id":"009-321-681-599-674","lens_id":["022-222-851-111-449","009-321-681-599-674","080-009-006-092-456"],"sequence":153,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":55,"text":"Examiner's 2nd Report issued in New Zealand Application No. 568611, dated Jun. 3, 2011.","npl_type":"a","external_id":[],"lens_id":[],"sequence":154,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":56,"text":"Fenteany et al., \"Lactacystin, proteasome function and cell fate,\" J. Biol. Chem., vol. 273, No. 15, pp. 8545-8548 (1998).","npl_type":"a","external_id":["10.1074/jbc.273.15.8545","9535824"],"record_lens_id":"010-031-437-446-713","lens_id":["173-170-043-713-429","010-031-437-446-713","017-180-487-805-159"],"sequence":155,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":57,"text":"Frank, \"Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors,\" American Journal of Opthamology, vol. 133, No. 5, pp. 693-698 (2002).","npl_type":"a","external_id":["11992868","10.1016/s0002-9394(02)01321-1"],"record_lens_id":"130-584-168-739-040","lens_id":["159-973-304-402-082","130-584-168-739-040","145-925-276-665-98X"],"sequence":156,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":58,"text":"Goekijan, \"Protein kinase C in the treatment of disease: Signal transduction pathways, inhibitors, and agents in development,\" Current Medical Chemistry, vol. 6, No. 9, pp. 877-903 (1999).","npl_type":"a","external_id":["10495357"],"record_lens_id":"079-276-830-993-640","lens_id":["114-805-545-855-618","079-276-830-993-640"],"sequence":157,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":59,"text":"Gomes-Marcondes et al., \"Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor,\" British Journal of Cancer, vol. 86, No. 10, pp. 1628-1633 (2002).","npl_type":"a","external_id":["10.1038/sj.bjc.6600236","pmc2746596","12085214"],"record_lens_id":"027-130-893-669-225","lens_id":["196-894-435-734-075","027-130-893-669-225","108-925-846-805-98X"],"sequence":158,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":60,"text":"Jagoe, \"What do we really know about the ubiquitin-proteasome pathway in muscle atrophy?\" Current Opinion in Clinical Nutrition and Metabolic Care, vol. 4, No. 3, pp. 183-190 (2001).","npl_type":"a","external_id":["10.1097/00075197-200105000-00003","11517350"],"record_lens_id":"033-091-204-120-201","lens_id":["130-133-530-223-686","033-091-204-120-201","167-756-830-652-97X"],"sequence":159,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":61,"text":"Meier, \"Protein kinase C activation and its pharmacological inhibition in vascular disease,\" Vascular Medicine, vol. 5, No. 3, pp. 173-185 (2000).","npl_type":"a","external_id":["11104300","10.1177/1358836x0000500307","10.1191/135886300701568405"],"record_lens_id":"007-812-331-521-07X","lens_id":["058-970-736-744-435","007-812-331-521-07X","160-582-874-385-461","174-090-032-479-290","189-330-497-145-543"],"sequence":160,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":62,"text":"Moscat, \"NF-kappaB activation by protein kinase C isoforms and B-cell function,\" EMBO Reports, vol. 4, No. 1, pp. 31-36 (2003).","npl_type":"a","external_id":["12524517","pmc1315804","10.1038/sj.embor.embor704"],"record_lens_id":"012-413-811-614-382","lens_id":["075-270-514-811-750","012-413-811-614-382","144-551-997-253-459"],"sequence":161,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":63,"text":"O'Brianne et al., \"The tumor promoter receptor protein kinase C: A novel target for chemoprevention and therapy of human colon cancer,\" Prog. Clin. Bio. Res., vol. 391, pp. 117-120 (1995).","npl_type":"a","external_id":["8532710"],"record_lens_id":"014-833-203-720-863","lens_id":["043-009-149-187-581","014-833-203-720-863"],"sequence":162,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":64,"text":"Orino et al., \"ATP-dependent reversible association of proteasomes with mutliple protein components to form 26S complexes that degrade ubiquitinated proteins in human HL-60 cells,\" FEBS Letters, vol. 284, No. 2, pp. 206-210 (1991).","npl_type":"a","external_id":["10.1016/0014-5793(91)80686-w","1647982"],"record_lens_id":"128-957-362-872-125","lens_id":["195-536-244-423-155","128-957-362-872-125","137-816-968-462-953"],"sequence":163,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":65,"text":"Ostaszewski et al., \"3-hydroxy-3-methylbutyrate and 2-oxoisocaproate effect body composition and cholestreol concentration in rabbits.\" Journal of Animal Physiology and Animal Nutrition, vol. 79, pp. 135-145 (1998).","npl_type":"a","external_id":["10.1111/j.1439-0396.1998.tb00637.x"],"record_lens_id":"071-826-184-062-982","lens_id":["130-749-127-321-935","071-826-184-062-982"],"sequence":164,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":66,"text":"Schols, \"Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease,\" Thorax, vol. 51, No. 8, pp. 819-824 (1996).","npl_type":"a","external_id":["pmc472555","10.1136/thx.51.8.819","8795671"],"record_lens_id":"103-330-126-274-127","lens_id":["154-001-675-903-347","103-330-126-274-127","197-600-444-102-088"],"sequence":165,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":67,"text":"Schols, \"Pulmonary cachexia,\" International Journal of Cardiology, vol. 85, No. 1, pp. 101-110 (2002).","npl_type":"a","external_id":["12163214","10.1016/s0167-5273(02)00238-3"],"record_lens_id":"029-644-032-765-320","lens_id":["029-644-032-765-320","195-340-333-617-846","182-457-892-529-938"],"sequence":166,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":68,"text":"Smart et al, \"Polyclonal and allergen-induced cytokine responses in adults . . . \" Journal of Allergy and Clinical Immunology, vol. 110, pp. 45-46 (2002).","npl_type":"a","external_id":[],"lens_id":[],"sequence":167,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":69,"text":"Smith et al., \"Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid,\" Cancer Research, vol. 59, No. 21, pp. 5507-5513 (1999).","npl_type":"a","external_id":["10554027"],"record_lens_id":"034-234-661-430-020","lens_id":["155-145-791-050-90X","034-234-661-430-020"],"sequence":168,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":70,"text":"Smith et al., \"Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes,\" British Journal of Cancer, vol. 89, No. 9, pp. 1783-1788 (2003).","npl_type":"a","external_id":["14583784","pmc2394402","10.1038/sj.bjc.6601328"],"record_lens_id":"077-871-978-623-615","lens_id":["155-946-767-104-269","077-871-978-623-615","084-283-194-945-635"],"sequence":169,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":71,"text":"Takabatake et al., \"Circulating leptin in patients with chronic obstructive pulmonary disease,\" American Journal of Respiratory and Critical Care Medicine, vol. 159, pp. 1215-1219 (1999).","npl_type":"a","external_id":["10194168","10.1164/ajrccm.159.4.9806134"],"record_lens_id":"082-641-568-165-364","lens_id":["169-891-394-737-356","082-641-568-165-364","153-088-331-331-080"],"sequence":170,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":72,"text":"Teixeira et al., \"The role of interferon-c on immune and allergic responses . . . , \" Mem. Inst. Oswaldo Cruz, vol. 100, pp. 137-144 (2005).","npl_type":"a","external_id":["15962113","10.1590/s0074-02762005000900024"],"record_lens_id":"030-508-566-147-200","lens_id":["142-623-182-000-79X","030-508-566-147-200","174-746-715-009-676"],"sequence":171,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":73,"text":"Todorov et al., \"Characterization of a cancer cachectic factor,\" Nature, vol. 379, No. 6567, pp. 739-742 (1996).","npl_type":"a","external_id":["10.1038/379739a0","8602222"],"record_lens_id":"098-662-996-880-51X","lens_id":["165-282-998-636-047","098-662-996-880-51X","187-749-601-853-225"],"sequence":172,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":74,"text":"Todorov et al., \"Induction of muscle protein degradation and weight loss by a tumor product,\" Cancer Research, vol. 56, No. 6, pp. 1256-1261 (1996).","npl_type":"a","external_id":["8640810"],"record_lens_id":"157-132-802-798-383","lens_id":["162-440-273-277-114","157-132-802-798-383"],"sequence":173,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":75,"text":"Toker, \"Signaling through protein kinase C,\" Frontiers in Bioscience, vol. 3, pp. 1134-1147 (1998).","npl_type":"a","external_id":["10.2741/a350","9792904"],"record_lens_id":"006-330-192-074-469","lens_id":["041-348-454-562-652","006-330-192-074-469","149-578-843-313-086"],"sequence":174,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":76,"text":"Van Koevering et al., \"Effects of b-hydroxy-b-methylbutyrate on performance and carcass quality of feedlot steers.\" Journal of Animal Science, vol. 72, pp. 1927-1935 (1994).","npl_type":"a","external_id":["7982819","10.2527/1994.7281927x"],"record_lens_id":"049-478-208-892-206","lens_id":["191-115-220-558-310","049-478-208-892-206","084-845-938-730-250"],"sequence":175,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":77,"text":"Waalkes, \"A fluorometric method for the estimation of tyrosine in plasma and tissues,\" Journal of Laboratory and Clinical Medicine, vol. 50, No. 5, pp. 733-736 (1957).","npl_type":"a","external_id":["13476030"],"record_lens_id":"057-510-235-772-485","lens_id":["069-084-639-481-445","057-510-235-772-485"],"sequence":176,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":78,"text":"Watchorn et al., \"Proteolysis-inducing factor regulates hepatic gene expression via the transcriptionfactor NF-kappaB and STST3,\" FASEB Journal, vol. 15, No. 3, pp. 562-564 (2001).","npl_type":"a","external_id":["11259367","10.1096/fj.00-0534fje"],"record_lens_id":"025-813-054-727-164","lens_id":["036-821-567-613-022","025-813-054-727-164","133-441-945-451-203"],"sequence":177,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":79,"text":"Whitehouse et al., \"Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin-proteasome pathway,\" British Journal of Cancer, vol. 89, No. 4, pp. 737-745 (2003).","npl_type":"a","external_id":["10.1038/sj.bjc.6601184","12915888","pmc2376908"],"record_lens_id":"020-560-313-341-342","lens_id":["133-820-048-396-312","020-560-313-341-342","045-042-086-784-502"],"sequence":178,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":80,"text":"Whitehouse et al., \"Increased expression of the ubiquitin-proteosome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB,\" British Journal of Cancer, vol. 89, No. 6, pp. 1116-1122 (2003).","npl_type":"a","external_id":["10.1038/sj.bjc.6601132","pmc2376944","12966435"],"record_lens_id":"034-060-577-252-586","lens_id":["109-162-196-229-493","034-060-577-252-586","166-676-932-860-693"],"sequence":179,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":81,"text":"Wolf et al., \"The mitogen-activated protein kinase signaling cascade: from bench to bedside,\" IMAJ, vol. 4, No. 8, pp. 641-647 (2002).","npl_type":"a","external_id":["12183875"],"record_lens_id":"047-062-124-201-509","lens_id":["067-698-124-692-941","047-062-124-201-509"],"sequence":180,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":82,"text":"Haumann, \"Structured Lipids Allow Fat Tailoring,\" International News on Fats, Oils, and Related Materials, vol. 8(10), pp. 1004-1011 (1997).","npl_type":"a","external_id":[],"lens_id":[],"sequence":181,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":83,"text":"Ho et al., \"Antioxidants, NFkappaB activation and diabetogenesis,\" Proceedings of the Society for Experimental Biology and Medicine, vol. 222, No. 3, pp. 205-213 (1999).","npl_type":"a","external_id":["10.1046/j.1525-1373.1999.d01-137.x","10601879"],"record_lens_id":"015-127-203-922-965","lens_id":["051-884-105-003-352","015-127-203-922-965","147-811-298-302-546"],"sequence":182,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":84,"text":"Kutsuzawa et al., \"Muscle energy metabolism and nutritional status in patients with chronic obstructive pulmonary disease,\" American Journal of Respiratory and Critical Care Medicine, vol. 152, No. 2, pp. 647-652 (1995).","npl_type":"a","external_id":["7633721","10.1164/ajrccm.152.2.7633721"],"record_lens_id":"029-425-593-819-085","lens_id":["127-699-882-482-424","029-425-593-819-085","198-306-585-560-807"],"sequence":183,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":85,"text":"Lorite et al., \"Activation of a TP-ubiquita-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF),\" British Journal of Cancer, vol. 85, No. 2, pp. 297-302 (2001).","npl_type":"a","external_id":["11461093","10.1054/bjoc.2001.1879","pmc2364050"],"record_lens_id":"157-803-476-895-149","lens_id":["177-034-015-188-312","157-803-476-895-149","168-993-164-967-923"],"sequence":184,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":86,"text":"Merck Index No. 1862, 2003.","npl_type":"a","external_id":[],"lens_id":[],"sequence":185,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":87,"text":"Merck Index No. 5198, 2003.","npl_type":"a","external_id":[],"lens_id":[],"sequence":186,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":88,"text":"Merck Index No. 7355, 2003.","npl_type":"a","external_id":[],"lens_id":[],"sequence":187,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":89,"text":"Merck Index No. 9908, 2003.","npl_type":"a","external_id":[],"lens_id":[],"sequence":188,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":90,"text":"Merck Index No. 9975, 2003.","npl_type":"a","external_id":[],"lens_id":[],"sequence":189,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":91,"text":"International Search Report and Written Opinion for PCT/US2011/039170, dated Aug. 3, 2011.","npl_type":"a","external_id":[],"lens_id":[],"sequence":190,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":92,"text":"European Search Report for App. 10186645.7-1216, dated Feb. 14, 2011.","npl_type":"a","external_id":[],"lens_id":[],"sequence":191,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":93,"text":"Golubitskii et al., \"Stability of Ascorbic Acid in Aqueous and Aqueous-Organic Solutions for Quantitative Determination,\" J. Anal Chem., vol. 62, No. 8, pp. 742-747 (2007).","npl_type":"a","external_id":["10.1134/s1061934807080096"],"record_lens_id":"120-915-324-921-153","lens_id":["180-073-288-365-564","120-915-324-921-153"],"sequence":192,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":94,"text":"Puspitasari et al., \"Calcium Fortification of Cottage Cheese with Hydrocolloid Control of Bitter Flavor Defects,\" J. Dairy Sci., vol. 74, pp. 1-7 (1991).","npl_type":"a","external_id":["10.3168/jds.s0022-0302(91)78136-8"],"record_lens_id":"024-332-681-872-041","lens_id":["105-548-230-594-993","024-332-681-872-041"],"sequence":193,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":95,"text":"Toelstede et al., \"Sensomics Mapping and Identification of the Key Bitter Metabolites in Gouda Cheese,\" J Agric Food Chem, vol. 56, pp. 2795-2804 (2008).","npl_type":"a","external_id":["10.1021/jf7036533","18355023"],"record_lens_id":"005-426-685-138-758","lens_id":["143-561-474-104-780","130-043-502-951-417","005-426-685-138-758"],"sequence":194,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":96,"text":"Toelstede et al., \"Quantitative Studies and Taste Re-Engineering Experiments Toward the Decoding of the Nonvolatile Sensometabolome of Gouda Cheese,\" J Agric Food Chem, vol. 56, pp. 5299-5307 (2008).","npl_type":"a","external_id":["10.1021/jf800552n","18557618"],"record_lens_id":"105-113-662-239-036","lens_id":["139-532-524-656-501","199-860-753-005-787","105-113-662-239-036"],"sequence":195,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":97,"text":"Tordoff et al., \"Vegetable Bitterness is Related to Calcium Content,\" Appitite, vol. 52, pp. 498-504 (2009).","npl_type":"a","external_id":["19260165","pmc2768385","10.1016/j.appet.2009.01.002"],"record_lens_id":"018-846-647-207-807","lens_id":["104-027-825-953-406","162-818-060-107-906","018-846-647-207-807"],"sequence":196,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":98,"text":"Engel et al., \"Evolution of the Composition of a Selected Bitter Camembert Cheese During Ripening: Release and Migration of Taste-Active Compounds,\" J. Agric Food Chem, vol. 49, pp. 2940-2947 (2001).","npl_type":"a","external_id":["10.1021/jf000966u","11409990"],"record_lens_id":"121-664-257-261-118","lens_id":["147-883-126-305-217","121-664-257-261-118","144-463-821-181-906"],"sequence":197,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}},{"npl":{"num":99,"text":"Engel et al., \"Evolution of the Taste of a Bitter Camembert Cheese During Ripening: Characterization of a Matrix Effect,\" J. Agric Food Chem., vol. 49, pp. 2930-2939 (2001).","npl_type":"a","external_id":["11409989","10.1021/jf000967m"],"record_lens_id":"026-144-651-153-753","lens_id":["087-366-947-779-321","026-144-651-153-753","159-270-766-125-939"],"sequence":198,"category":[],"us_category":[],"cited_phase":"APP","rel_claims":[]}}],"reference_cited.source":"DOCDB","reference_cited.patent_count":99,"cites_patent":true,"reference_cited.npl_count":100,"reference_cited.npl_resolved_count":62,"cites_npl":true,"cites_resolved_npl":true,"cited_by":{"patent_count":0,"patent":[]},"cited_by_patent":false,"family":{"simple":{"size":38,"id":190199778,"member":[{"lens_id":"087-299-670-904-718","document_id":{"jurisdiction":"CN","doc_number":"102225060","kind":"A","date":"2011-10-26"}},{"lens_id":"172-725-652-009-744","document_id":{"jurisdiction":"US","doc_number":"8778992","kind":"B2","date":"2014-07-15"}},{"lens_id":"144-965-630-942-389","document_id":{"jurisdiction":"US","doc_number":"20120178811","kind":"A1","date":"2012-07-12"}},{"lens_id":"116-331-952-844-810","document_id":{"jurisdiction":"CR","doc_number":"10085","kind":"A","date":"2008-08-06"}},{"lens_id":"106-673-547-590-412","document_id":{"jurisdiction":"AU","doc_number":"2006331950","kind":"A1","date":"2007-07-05"}},{"lens_id":"087-047-839-950-71X","document_id":{"jurisdiction":"RU","doc_number":"2011133891","kind":"A","date":"2013-02-20"}},{"lens_id":"136-243-134-888-139","document_id":{"jurisdiction":"RU","doc_number":"2008129605","kind":"A","date":"2010-01-27"}},{"lens_id":"081-664-142-672-890","document_id":{"jurisdiction":"JP","doc_number":"5696168","kind":"B2","date":"2015-04-08"}},{"lens_id":"167-113-666-393-777","document_id":{"jurisdiction":"EP","doc_number":"1968564","kind":"B1","date":"2015-09-16"}},{"lens_id":"120-954-513-287-333","document_id":{"jurisdiction":"US","doc_number":"8796333","kind":"B2","date":"2014-08-05"}},{"lens_id":"019-446-100-643-932","document_id":{"jurisdiction":"JP","doc_number":"2009520029","kind":"A","date":"2009-05-21"}},{"lens_id":"149-778-541-708-353","document_id":{"jurisdiction":"TW","doc_number":"200800151","kind":"A","date":"2008-01-01"}},{"lens_id":"103-906-549-340-375","document_id":{"jurisdiction":"CA","doc_number":"2632262","kind":"A1","date":"2007-07-05"}},{"lens_id":"163-458-368-318-187","document_id":{"jurisdiction":"TW","doc_number":"I424840","kind":"B","date":"2014-02-01"}},{"lens_id":"092-419-583-670-292","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"A1","date":"2009-07-29"}},{"lens_id":"069-664-200-513-616","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"A8","date":"2010-06-23"}},{"lens_id":"181-598-293-180-28X","document_id":{"jurisdiction":"US","doc_number":"20120189709","kind":"A1","date":"2012-07-26"}},{"lens_id":"107-313-744-815-219","document_id":{"jurisdiction":"JP","doc_number":"5227182","kind":"B2","date":"2013-07-03"}},{"lens_id":"152-492-436-368-62X","document_id":{"jurisdiction":"NZ","doc_number":"568611","kind":"A","date":"2011-11-25"}},{"lens_id":"039-977-955-638-432","document_id":{"jurisdiction":"BR","doc_number":"PI0620083","kind":"A2","date":"2011-11-01"}},{"lens_id":"016-288-039-422-11X","document_id":{"jurisdiction":"WO","doc_number":"2007075605","kind":"A3","date":"2008-06-26"}},{"lens_id":"103-518-175-949-121","document_id":{"jurisdiction":"CN","doc_number":"101374509","kind":"B","date":"2013-06-19"}},{"lens_id":"182-131-861-751-51X","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"B1","date":"2015-09-16"}},{"lens_id":"178-322-761-667-65X","document_id":{"jurisdiction":"ZA","doc_number":"200805297","kind":"B","date":"2009-05-27"}},{"lens_id":"135-729-541-076-684","document_id":{"jurisdiction":"US","doc_number":"20120177744","kind":"A1","date":"2012-07-12"}},{"lens_id":"060-897-759-883-853","document_id":{"jurisdiction":"EP","doc_number":"1968564","kind":"A2","date":"2008-09-17"}},{"lens_id":"160-707-765-525-732","document_id":{"jurisdiction":"NZ","doc_number":"593182","kind":"A","date":"2012-09-28"}},{"lens_id":"184-236-020-953-508","document_id":{"jurisdiction":"CA","doc_number":"2632262","kind":"C","date":"2015-04-07"}},{"lens_id":"093-352-871-870-160","document_id":{"jurisdiction":"ES","doc_number":"2548432","kind":"T3","date":"2015-10-16"}},{"lens_id":"053-765-054-868-161","document_id":{"jurisdiction":"CN","doc_number":"101374509","kind":"A","date":"2009-02-25"}},{"lens_id":"168-993-865-116-558","document_id":{"jurisdiction":"WO","doc_number":"2007075605","kind":"A2","date":"2007-07-05"}},{"lens_id":"050-065-869-418-94X","document_id":{"jurisdiction":"RU","doc_number":"2469719","kind":"C2","date":"2012-12-20"}},{"lens_id":"123-518-067-227-469","document_id":{"jurisdiction":"ES","doc_number":"2548305","kind":"T3","date":"2015-10-15"}},{"lens_id":"094-179-814-162-432","document_id":{"jurisdiction":"EC","doc_number":"SP088539","kind":"A","date":"2008-07-30"}},{"lens_id":"087-252-837-094-756","document_id":{"jurisdiction":"SV","doc_number":"2009002948","kind":"A","date":"2009-02-19"}},{"lens_id":"029-487-766-828-603","document_id":{"jurisdiction":"US","doc_number":"20070142469","kind":"A1","date":"2007-06-21"}},{"lens_id":"127-207-253-692-150","document_id":{"jurisdiction":"JP","doc_number":"2013136587","kind":"A","date":"2013-07-11"}},{"lens_id":"186-121-472-141-490","document_id":{"jurisdiction":"MY","doc_number":"180733","kind":"A","date":"2020-12-08"}}]},"extended":{"size":38,"id":190100220,"member":[{"lens_id":"087-299-670-904-718","document_id":{"jurisdiction":"CN","doc_number":"102225060","kind":"A","date":"2011-10-26"}},{"lens_id":"172-725-652-009-744","document_id":{"jurisdiction":"US","doc_number":"8778992","kind":"B2","date":"2014-07-15"}},{"lens_id":"144-965-630-942-389","document_id":{"jurisdiction":"US","doc_number":"20120178811","kind":"A1","date":"2012-07-12"}},{"lens_id":"116-331-952-844-810","document_id":{"jurisdiction":"CR","doc_number":"10085","kind":"A","date":"2008-08-06"}},{"lens_id":"106-673-547-590-412","document_id":{"jurisdiction":"AU","doc_number":"2006331950","kind":"A1","date":"2007-07-05"}},{"lens_id":"087-047-839-950-71X","document_id":{"jurisdiction":"RU","doc_number":"2011133891","kind":"A","date":"2013-02-20"}},{"lens_id":"136-243-134-888-139","document_id":{"jurisdiction":"RU","doc_number":"2008129605","kind":"A","date":"2010-01-27"}},{"lens_id":"081-664-142-672-890","document_id":{"jurisdiction":"JP","doc_number":"5696168","kind":"B2","date":"2015-04-08"}},{"lens_id":"167-113-666-393-777","document_id":{"jurisdiction":"EP","doc_number":"1968564","kind":"B1","date":"2015-09-16"}},{"lens_id":"120-954-513-287-333","document_id":{"jurisdiction":"US","doc_number":"8796333","kind":"B2","date":"2014-08-05"}},{"lens_id":"019-446-100-643-932","document_id":{"jurisdiction":"JP","doc_number":"2009520029","kind":"A","date":"2009-05-21"}},{"lens_id":"149-778-541-708-353","document_id":{"jurisdiction":"TW","doc_number":"200800151","kind":"A","date":"2008-01-01"}},{"lens_id":"103-906-549-340-375","document_id":{"jurisdiction":"CA","doc_number":"2632262","kind":"A1","date":"2007-07-05"}},{"lens_id":"163-458-368-318-187","document_id":{"jurisdiction":"TW","doc_number":"I424840","kind":"B","date":"2014-02-01"}},{"lens_id":"092-419-583-670-292","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"A1","date":"2009-07-29"}},{"lens_id":"069-664-200-513-616","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"A8","date":"2010-06-23"}},{"lens_id":"181-598-293-180-28X","document_id":{"jurisdiction":"US","doc_number":"20120189709","kind":"A1","date":"2012-07-26"}},{"lens_id":"107-313-744-815-219","document_id":{"jurisdiction":"JP","doc_number":"5227182","kind":"B2","date":"2013-07-03"}},{"lens_id":"152-492-436-368-62X","document_id":{"jurisdiction":"NZ","doc_number":"568611","kind":"A","date":"2011-11-25"}},{"lens_id":"039-977-955-638-432","document_id":{"jurisdiction":"BR","doc_number":"PI0620083","kind":"A2","date":"2011-11-01"}},{"lens_id":"016-288-039-422-11X","document_id":{"jurisdiction":"WO","doc_number":"2007075605","kind":"A3","date":"2008-06-26"}},{"lens_id":"103-518-175-949-121","document_id":{"jurisdiction":"CN","doc_number":"101374509","kind":"B","date":"2013-06-19"}},{"lens_id":"182-131-861-751-51X","document_id":{"jurisdiction":"EP","doc_number":"2082738","kind":"B1","date":"2015-09-16"}},{"lens_id":"178-322-761-667-65X","document_id":{"jurisdiction":"ZA","doc_number":"200805297","kind":"B","date":"2009-05-27"}},{"lens_id":"135-729-541-076-684","document_id":{"jurisdiction":"US","doc_number":"20120177744","kind":"A1","date":"2012-07-12"}},{"lens_id":"060-897-759-883-853","document_id":{"jurisdiction":"EP","doc_number":"1968564","kind":"A2","date":"2008-09-17"}},{"lens_id":"160-707-765-525-732","document_id":{"jurisdiction":"NZ","doc_number":"593182","kind":"A","date":"2012-09-28"}},{"lens_id":"184-236-020-953-508","document_id":{"jurisdiction":"CA","doc_number":"2632262","kind":"C","date":"2015-04-07"}},{"lens_id":"093-352-871-870-160","document_id":{"jurisdiction":"ES","doc_number":"2548432","kind":"T3","date":"2015-10-16"}},{"lens_id":"053-765-054-868-161","document_id":{"jurisdiction":"CN","doc_number":"101374509","kind":"A","date":"2009-02-25"}},{"lens_id":"168-993-865-116-558","document_id":{"jurisdiction":"WO","doc_number":"2007075605","kind":"A2","date":"2007-07-05"}},{"lens_id":"050-065-869-418-94X","document_id":{"jurisdiction":"RU","doc_number":"2469719","kind":"C2","date":"2012-12-20"}},{"lens_id":"123-518-067-227-469","document_id":{"jurisdiction":"ES","doc_number":"2548305","kind":"T3","date":"2015-10-15"}},{"lens_id":"094-179-814-162-432","document_id":{"jurisdiction":"EC","doc_number":"SP088539","kind":"A","date":"2008-07-30"}},{"lens_id":"087-252-837-094-756","document_id":{"jurisdiction":"SV","doc_number":"2009002948","kind":"A","date":"2009-02-19"}},{"lens_id":"029-487-766-828-603","document_id":{"jurisdiction":"US","doc_number":"20070142469","kind":"A1","date":"2007-06-21"}},{"lens_id":"127-207-253-692-150","document_id":{"jurisdiction":"JP","doc_number":"2013136587","kind":"A","date":"2013-07-11"}},{"lens_id":"186-121-472-141-490","document_id":{"jurisdiction":"MY","doc_number":"180733","kind":"A","date":"2020-12-08"}}]}},"has_sequence":false,"legal_status":{"ipr_type":"patent for invention","granted":true,"earliest_filing_date":"2006-12-19","grant_date":"2014-08-05","anticipated_term_date":"2026-12-19","discontinuation_date":"2018-09-10","has_disclaimer":true,"patent_status":"INACTIVE","publication_count":2,"has_spc":false,"has_grant_event":false,"has_entry_into_national_phase":false},"abstract":{"en":[{"text":"Disclosed are methods of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokine production, wherein the method comprises administering to the individual an amount of β-hydroxy-β-methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type 1 to type 2 cytokines, including an increase in the ratio of type 1 to type 2 cytokines without a corresponding increase in type 2 cytokine levels. Also disclosed are methods of using HMB to treat asthma and allergies. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type 1 cytokines without a corresponding increase in type 2 cytokines.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"}]},"abstract_lang":["en"],"has_abstract":true,"claim":{"en":[{"text":"1. A method of treating an individual having a condition characterized by a higher relative ratio of type 2 cytokines to type 1 cytokines, the method comprising administering to the individual a composition comprising an effective amount of β-hydroxy-β-methylbutyrate to increase the relative ratio of type 1 to type 2 cytokines, wherein said treating consists of at least one of delaying the onset of said condition and reducing the severity of symptoms of said condition, and wherein said condition is selected from the group consisting of allergy and asthma.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"2. The method of claim 1 wherein the level of type 1 cytokines is increased by the administration of β-hydroxy-β-methylbutyrate without an increase in type 2 cytokines.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"3. The method of claim 1 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.1 grams to 10 grams per day.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"4. The method of claim 3 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.5 grams to 10 grams per day.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"5. The method of claim 4 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.5 grams to 5.0 grams per day.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"6. The method of claim 5 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 1.0 grams to 3.5 grams per day.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"7. The method of claim 1 wherein the composition further comprises one or more of fat, protein, and carbohydrate.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"8. The method of claim 1 wherein the condition is an allergy.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"9. The method of claim 8 wherein the amount of β-hydroxy-β-methylbutyrate is effective to ameliorate symptoms of said allergy.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"10. The method of claim 8 wherein the allergy is selected from the group consisting of hay fever, food allergies, allergic conjunctivitis, atopic dermatitis, and inhalant allergies.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"11. The method of claim 1 wherein the condition is asthma.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"12. The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is effective to ameliorate symptoms of said asthma.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"13. The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is effective to prevent a decrease in forced expiratory volume in 1 second (FEV 1 ).","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"14. The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is sufficient to maintain basal forced expiratory volume in 1 second (FEV 1 ) above 80%.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"15. The method of claim 1 wherein the type 1 cytokine is selected from the group consisting of interferon-γ, interleukin 2, and interleukin 12.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"16. The method of claim 15 wherein the type 1 cytokine is interferon-γ or interleukin 2.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"17. The method of claim 1 wherein the type 2 cytokine is selected from the group consisting of interleukin 4, interleukin 5, interleukin 13, and interleukin 10.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"18. The method of claim 17 wherein the type 2 cytokine is interleukin 4.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"},{"text":"19. The method of claim 1 wherein the composition further comprises a mineral selected from the group consisting of calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, chloride, and combinations thereof.","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"}]},"claim_lang":["en"],"has_claim":true,"description":{"en":{"text":"This application is a divisional of U.S. application Ser. No. 11/641,978 filed Dec. 19, 2006, which claims the benefit of U.S. Provisional Patent Application 60/752,253 filed Dec. 19, 2005, the entire disclosures of which are incorporated herein by reference. TECHNICAL FIELD The present invention relates to a method of treating individuals with β-hydroxy-β-methylbutyrate (HMB) to modulate cytokine production. BACKGROUND OF THE INVENTION Allergies and asthma in the industrialized world have increased in prevalence and severity over recent years. Asthma is now, in fact, the most common chronic illness among children. Much is known about the pathogenesis of allergies and asthma. Both are immune-based diseases. Both are associated with an imbalance in the relative levels of type-1 and type-2 cytokines in the body. It has been observed that individuals with allergies or asthma have a higher relative ratio of type 2 to type 1 cytokines. It is believed that this skewed ratio then contributes to the pathogenesis of allergies and asthma. In general, cytokines are cell-produced regulatory proteins that influence, in paracrine or autocrine fashion, cell function. They are produced by immune cells and are therefore categorized by their inducible function and the cell types involved in the response. Type 1 cytokines, for example, elicit or augment primarily cell-mediated immune responses against pathogens. Type 1 cytokines are involved in inflammatory responses, viral immunity, intracellular parasite immunity and allograft rejection. Type 1 cytokines include interleukin 2 (IL-2), interleukin 12 (IL-12), and interferon γ (IFNγ). Type 1 cytokines can suppress the production of type 2 cytokines. Type 2 cytokines, by contrast, elicit or augment primarily antibody-mediated immune responses against pathogens. Type 2 cytokines are involved in humoral responses, helminth immunity, and allergic responses. Type 2 cytokines include interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 10 (IL-10), and interleukin 13 (IL-13). Type 2 cytokines can suppress the production of type 1 cytokines. Given the association between cytokine imbalance in allergies and asthma, it is believed that therapies directed to the normalization of the ratio of type 1 to type 2 cytokine levels will help treat or even prevent such diseases. To that end, it has now been discovered herein that β-hydroxy-β-methylbutyrate (HMB) exposure (in vitro) increases the relative ratio of type-1 to type-2 cytokines in stimulated peripheral blood mononuclear cells (PBMC), thus providing a potential new therapy for treating individuals having or at risk for developing allergies and asthma. As a commercially available ingredient, HMB is found in a variety of nutritional products. It is also a metabolite of the essential amino acid leucine and is therefore found naturally in the human body. HMB is also found in a variety of plants, including citrus fruits and alfalfa, as well as in catfish. It is also known and used for a variety of purposes, including to build or maintain muscle mass in appropriate individuals and to enhance overall immune function. To date, however, there have been no reports on the effect of HMB in modulating type 1 and type 2 cytokine production nor any disclosure of the use of HMB to affect cytokine imbalance in treating conditions responsive thereto, including allergies and asthma. SUMMARY OF THE INVENTION The methods of the present invention are directed to the modulation of type 1 to type 2 cytokine levels in the body in those individuals afflicted with conditions characterized by a corresponding cytokine imbalance, to thus provide treatment of the underlying condition. Most notable among such conditions are allergies and asthma. A first embodiment of the present invention is a method of treating an individual having a condition characterized by a relative imbalance of type 1 to type 2 cytokine levels in the body, wherein the method comprises the administration to the individual of an effective amount of β-hydroxy-β-methylbutyrate to thus modulate the imbalance, typically by increasing the relative levels or production of type 1 to type 2 cytokines. The present invention includes those embodiments in which the condition is asthma, allergies, or both. A second embodiment of the present invention is a method of treating an individual having or at risk for developing allergies, the method comprising the administration to the individual an effective amount of β-hydroxy-β-methylbutyrate (HMB). A third embodiment of the present invention is a method of treating individuals having or at risk for developing asthma, the method comprising the administration to the individual an effective amount of β-hydroxy-β-methylbutyrate (HMB). A fourth embodiment of the present invention is a method of treating elderly individuals at risk for developing age-related infections, the method comprising the administration to such individuals an effective amount of β-hydroxy-β-methylbutyrate (HMB). The present invention is based upon the discovery that peripheral blood mononuclear cells (PBMC) stimulated with the T cell stimulus CD3/CD28 and simultaneously exposed to HMB exhibit a shift in type 1 and type 2 cytokine production, favoring type 1 cytokine production. The shift occurs as HMB exposure increases the production of type 1 cytokines such as interferon-γ (IFNγ), interleukin 12 (IL-12), and interleukin 2 (IL-2), without a corresponding increase in the production of type 2 cytokines such as interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 10 (IL-10), and interleukin 13 (IL-13). BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 summarizes experimental data showing the effect of HMB on type 1 cytokine (IL-2, IL-12, IFNγ, TNFα, GM-CSF) production from peripheral blood mononuclear cells simultaneously stimulated with CD3/CD28 for 24 hours (*p<0.05, paired sample, 2 tailed t-test, comparison to no HMB). FIG. 2 summarizes experimental data showing the effect of HMB on type 2 cytokine (IL-4, IL-5, IL-10, IL-13) production from peripheral blood mononuclear cells simultaneously stimulated with CD3/CD28 for 24 hours (*p<0.05, paired sample, 2 tailed t-test, comparison to no HMB). FIG. 3 summarizes experimental data showing the effect of HMB on the ratio cytokine type 1 (IL-2) to type 2 cytokines (IL-4, IL-5, IL-13, IL-10) from peripheral blood mononuclear cells simultaneously stimulated with CD3/CD28 for 24 hours (*p<0.05, paired sample, 2 tailed t-test, comparison to no HMB) FIG. 4 summarizes experimental data showing the effect of HMB on the ratio cytokine type 1 (IL-12) to type 2 cytokines (IL-4, IL-5, IL-13, IL-10) from peripheral blood mononuclear cells simultaneously stimulated with CD3/CD28 for 24 hours (*p<0.05, paired sample, 2 tailed t-test, comparison to no HMB) FIG. 5 summarizes experimental data showing the effect of HMB on the ratio cytokine type 1 (IFNγ) to type 2 cytokines (IL-4, IL-5, IL-13, IL-10) from peripheral blood mononuclear cells simultaneously stimulated with CD3/CD28 for 24 hours (*p<0.05, paired sample, 2 tailed t-test, comparison to no HMB) DETAILED DESCRIPTION The methods of the present invention comprise the administration of an effective amount of β-hydroxy-β-methylbutyrate (HMB) to an individual in need thereof in the manner and for the purposes described herein. These and other essential or optional elements or features of the methods of the present invention are described in detail hereinafter. The terms “treating” and “treatment” as used herein, unless otherwise specified, includes preventing a condition, delaying the onset of a condition, reducing the severity of symptoms of a condition, or eliminating some or all of the symptoms of a condition. The term “ameliorate” as used herein, unless otherwise specified, means to eliminate, delay, or reduce the prevalence or severity of symptoms associated with a condition. The term “condition” as used herein, unless otherwise specified, includes pathological and non-pathological conditions, all of which are characterized by an aberration or imbalance in the relative amounts of type 1 to type 2 cytokines. The term “elderly individual” as used herein, unless otherwise specified, means someone more than 60 years old, preferably more than 70 years old. The term “modulate” as used herein, unless otherwise specified, means to reduce the imbalance (i.e., imbalance associated with a condition) of type 1 to type 2 cytokine levels in the body, or to otherwise increase the ratio of type 1 to type 2 cytokines, including an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels. All percentages, parts and ratios as used herein are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified. All numerical ranges as used herein, whether or not expressly preceded by the term “about”, are intended and understood to be preceded by that term, unless otherwise specified. All references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made. All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made. The methods of the present invention may also be substantially free of any optional or selected essential feature described herein, provided that the remaining method still contains all of the required limitations as described herein. Embodiments We now turn to the first embodiment of the present invention. Conditions included within the first embodiment of the present invention include allergy, asthma, solid tumors, cancers including advanced ovarian cancer and melanoma, kidney tumors, and stress, including psychological stress after a burn injury, surgical stress and pre-surgical stress. The methods are especially useful in treating allergy, asthma, or both. With respect to allergy and asthma, elevated levels of IL-4, a type 2 cytokine, have been associated with the promotion or aggravation of allergy and asthma. Therefore, the first embodiment of the present invention, which is directed to a method of treating an individual having a condition comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, can treat individuals suffering from the symptoms of allergy and asthma because the increase in type 1 cytokines will serve to promote a balanced type 1 to type 2 cytokine profile. With respect to cancers, including advanced ovarian cancer, studies have shown that the direct injection into the abdominal cavity of the type 1 cytokine IFN-γ may prolong the survival time for women with advanced ovarian cancer. This treatment has been shown to be effective both during the initial chemotherapy as well as after chemotherapy for individuals in whom chemotherapy has failed. Therefore, the first embodiment of the present invention, which is directed to a method of treating an individual having a condition comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, potentiates treatment of individuals with cancer, including advanced ovarian cancer, because the method has been discovered to raise levels of type 1 cytokines, including IFNγ. With respect to kidney tumors and melanoma, studies have shown that interleukin 2 given as an injection under the skin can treat some kidney tumors and melanoma. When used as a cancer treatment, it is thought that IL-2 strengthens the body's natural defense mechanism and causes some cancer cells to be recognized and eliminated by immune cells. Therefore, the first embodiment of the present invention, which is directed to a method of treating an individual having a condition comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without an increase in type 2 cytokines, potentiates treatment of individuals having kidney tumors or melanoma because the inventors have discovered that the method of the first embodiment of the present invention can raise levels of type 1 cytokines, including IL-2. With respect to psychological stress after a burn injury, surgical stress and pre-surgical stress, studies have shown that stress increases type 2 and suppresses type 1 cytokine production. The immune system is compromised when individuals experience stress due to the production of type 2 cytokines and the suppression of type 1 cytokines that accompany periods of stress. Therefore, the first embodiment of the present invention, which is directed to a method of treating an individual having a condition comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without an increase in type 2 cytokines, can treat stress after a burn injury, surgical stress and pre-surgical stress because administering to individuals an amount of HMB effective to increase type 1 cytokine levels without increasing type 2 cytokine levels accommodates for the cytokine imbalance associated with stress. The increase in type 1 cytokines promotes a balanced type 1 to type 2 cytokine profile in the individual. The type 1 cytokines included within the first embodiment of the present invention include interferon-γ, interleukin 2, and interleukin 12. The type 2 cytokines included within the first embodiment of the present invention include interleukin 4, interleukin 5, interleukin 10, and interleukin 13. Some of the protective functions of IFNγ include inhibition of viral replication, stimulation of macrophages and enhancement of cell surface molecules necessary for self-recognition in an immune response. Additionally, adequate levels of IFNγ are required for protection against infection and disease. IFNγ also antagonizes several actions of type 2 cytokine IL-4 and inhibits the proliferation of IL-4 producing cells. Therefore, the ability to induce production of IFNγ aids in the treatment of individuals with conditions such as those discussed herein. The inventors have discovered that HMB can induce the production of IFNγ without affecting the production of type 2 cytokines and therefore the present method is effective in treating conditions of the type discussed herein. Some of the protective functions of IL-2 include inducing proliferation of all T cells, activated B cells, and natural killer cell and enhancing killing of tumor cells by the induction of tumoricidal cytokines from T cells and natural killer cells. Adequate levels of IL-2 are also required for protection against infection and disease. Therefore, the ability to induce production of IL-2 aids in the treatment of individuals with conditions such as those discussed herein. The inventors have discovered that administration of HMB induces the production of IL-2 without increasing the type 2 cytokine levels and therefore the present method is effective in treating conditions of the type discussed herein. While adequate levels of type 2 cytokine IL-4 are also required for protection against infection and disease, elevated levels of IL-4 have been associated with the promotion of allergies, asthma and stress. Therefore, the ability to treat an individual having a condition as described herein is dependent upon both the ability to induce the production of type 1 cytokines such as IFNγ and IL-2, but also the ability to not simultaneously increase the production of type 2 cytokines, and particularly IL-4, as increased levels of IL-4 are known to promote allergies, asthma and stress. The first embodiment of the present invention is directed to a method of treating an individual having a condition wherein the administration of HMB induces the production of IL-2 and IFNγ without a corresponding increase in IL-4 levels. Another aspect of the first embodiment of the present invention is directed to a method of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokines, comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, wherein the amount of HMB administered is an amount effective to ameliorate allergic symptoms. Elevated levels of type 2 cytokine IL-4 are associated with the promotion of allergies. But type 1 cytokines such as IFNγ antagonize several actions of IL-4 and inhibit the proliferation of IL-4 producing cells. Therefore, the present method is capable of ameliorating the symptoms of allergies when the amount of HMB administered to an individual is an effective amount to promote a balanced type 1 to type 2 cytokine profile. Similarly, the present invention is directed to a method of treating an individual having a condition characterized by an imbalance in type 1 and 2 cytokines, comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, wherein the amount of HMB administered is an amount effective to ameliorate asthmatic symptoms. Elevated levels of type 2 cytokine IL-4 are associated with the promotion of asthma. But type 1 cytokines such as IFNγ antagonize several actions of IL-4 and inhibits the proliferation of IL-4 producing cells. Therefore, the present method is capable of ameliorating the symptoms of asthma when the amount of HMB administered to an individual is an effective amount to promote a balanced type 1 to type 2 cytokine profile. Still another aspect of the first embodiment of the present invention is directed to a method of treating an individual having a condition characterized by an imbalance in type 1 and type 2 cytokines, comprising administering to the individual an amount of HMB effective to modulate or otherwise cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, wherein the amount of HMB administered is an amount effective to prevent a decrease in FEV 1 , or the forced expiratory volume in 1 second. Individuals suffering from severe and persistent asthma display a low FEV 1 percentage value, while those who suffer from only mild and intermittent asthma display a higher percentage value. Thus, in administering an amount of HMB effective to induce the production of type 1 cytokines without inducing the production of type 2 cytokines in order to decrease the promotion of asthma associated with imbalanced type 1 to type 2 cytokine profiles, the present method is capable of preventing a decrease in FEV 1 . Individuals who experience only mild and intermittent symptoms of asthma display a FEV 1 value of greater than or equal to 80%. Therefore, another aspect of the first embodiment of the present invention is directed to a method of treating an individual having a condition where cytokine production is induced, comprising administering to the individual an amount of HMB effective to cause an increase in type 1 cytokine levels without a corresponding increase in type 2 cytokine levels, wherein the amount of HMB administered is an amount effective to maintain basal FEV 1 above 80%. In altering the imbalanced type 1 to type 2 cytokine profiles associated with asthma through the method of the first embodiment of the present invention, the method is capable of maintaining basal FEV 1 above 80%. We now turn to the second embodiment of the present invention. The present invention includes a method of treating allergy in an individual having or at risk for developing allergy, the method comprising the administration to the individual an amount of β-hydroxy-β-methylbutyrate effective to prevent or ameliorate symptoms of allergies. Individuals who are at risk for allergy include those who are already suffering from allergies and those who are genetically or otherwise predisposed to having allergies. The term “allergies” as used herein includes hay fever, food allergies, allergic conjunctivitis, atopic dermatitis, inhalant (air born allergens) allergy, and other common allergies. Such allergies are often associated with exposure to allergens such as animal danders, pollens, insect stings or bites, house dust, house dust mites, molds, some drugs, and foods, especially fish, eggs, milk and nuts. We now turn to the third embodiment of the present invention. The present invention includes a method of treating asthma in an individual having or at risk for asthma, the method comprising the administration to the individual of an amount of β-hydroxy-β-methylbutyrate effective to prevent or ameliorate asthmatic symptoms. Individuals who are at risk for asthma include those who are already suffering from asthma and those who are genetically or otherwise predisposed to having asthma. We now turn to the fourth embodiment of the present invention. The present invention includes a method of treating elderly individuals at risk of developing age-related infections, including both bacterial and viral infections, respiratory and non-respiratory, the method comprising the administration to such individuals of an amount of β-hydroxy-β-methylbutyrate effective to reduce the risk or prevalence of such infections. An effective amount of HMB, for the purposes of the methods described herein, most typically ranges from 0.1 g to 10 g, including from 0.5 g to 5.0 g, and also including from 1.0 g to 3.5 g, of HMB per day. The total daily dose may be administered as a single, divided, or continuous (or semi-continuous) dose (e.g., enteral feeding), every day or on selected intermittent days. The methods of the present invention are preferably directed to oral administration. Product Forms The methods of the present invention may be directed to any product form suitable for the safe administration of an effective amount of HMB to the targeted population or selected individual, all in accordance with the methods herein. Such products include pharmaceutical dosage forms (e.g., capsules, tablets, liquids, topicals, etc.) as well as nutritional products. Nutritional products for use herein further comprise one or more (preferably all) of fat, protein, carbohydrate, minerals, and vitamins. Such products include solids, liquids, powders, and gels. Non-limiting examples of solid nutritional product forms suitable for use herein include snack and meal replacement products, including those formulated as bars, sticks, cookies or breads or cakes or other baked goods, frozen liquids, candy, breakfast cereals, powders or granulated solids or other particulates, snack chips or bites, and so forth. Non-limiting examples of liquid nutritional product forms suitable for use herein include snack and meal replacement products such as those formulated as juices or other acidified beverages, milk or soy-based beverages, shakes, coffees, teas, carbonated beverages, non-carbonated beverages, enteral feeding compositions, and so forth. These liquid compositions are most typically formulated as suspensions or emulsions, but can also be formulated in any other suitable form such as solutions, liquid gels, and so forth. Many different sources and types of proteins, lipids, and carbohydrates are known and can be used in the various nutritional products described herein, provided that the selected nutrients are safe and effective for oral administration and are compatible with the essential and other added ingredients. Carbohydrates suitable for use in the nutritional products may be simple, complex, or variations or combinations thereof. Non-limiting examples of suitable carbohydrates include hydrolyzed or modified starch or cornstarch, maltodextrin, glucose polymers, sucrose, corn syrup, corn syrup solids, rice-derived carbohydrate, glucose, fructose, lactose, high fructose corn syrup, indigestible oligosaccharides (e.g., fructooligosaccharides), honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), and combinations thereof. Carbohydrates suitable for use herein also include soluble dietary fiber, non-limiting examples of which include gum arabic, sodium carboxymethyl cellulose, guar gum, citrus pectin, low and high methoxy pectin, oat and barley glucans, carrageenan, psyllium and combinations thereof. Soluble dietary fiber is also suitable as a carbohydrate source herein, non-limiting examples of which include oat hull fiber, pea hull fiber, soy hull fiber, soy cotyledon fiber, sugar beet fiber, cellulose, corn bran, and combinations thereof. Proteins suitable for use in the nutritional products include hydrolyzed, partially hydrolyzed or non-hydrolyzed proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof. The proteins for use herein can also include, or be entirely or partially replaced by, free amino acids known for use in nutritional products, non-limiting examples of which include tryptophan, glutamine, tyrosine, methionine, cysteine, arginine, and combinations thereof. Fats suitable for use in the nutritional products include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, and combinations thereof. The concentration or amount of carbohydrate, protein, and carbohydrate in the nutritional compositions of the present invention can vary considerably depending upon the particular product form and the various other formulations and targeted dietary needs. These macronutrients are most typically formulated within any of the caloric ranges (embodiments A, B, or C) described in the following table. Nutritional EmbodimentsNutrientsABCCarbohydrate - % total calories1-9810-7530-50Fat - % total calories1-9820-8535-55Protein - % total calories1-985-7015-35 The nutritional compositions for use herein may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population. Many such optional ingredients are known or otherwise suitable for use in medical food or other nutritional products or pharmaceutical dosage forms and may also be used in the compositions herein, provided that such optional ingredients are safe for oral administration and are compatible with the essential and other ingredients in the selected product form. Non-limiting examples of such optional ingredients include preservatives, anti-oxidants, emulsifying agents, buffers, additional pharmaceutical actives, additional nutrients as described herein, sweeteners including artificial sweeteners (e.g., saccharine, aspartame, acesulfame K, sucralose) colorants, flavors, thickening agents and stabilizers, emulsifying agents, lubricants, and so forth. The nutritional compositions for use herein may further comprise any of a variety of other vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin D, vitamin E, vitamin K, thiamine, riboflavin, pyridoxine, vitamin B 12 , carotenoids (e.g., beta-carotene, zeaxanthin, lutein, lycopene), niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof. The nutritional compositions for use herein may further comprise any of a variety of other additional minerals, non-limiting examples of which include calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, chloride, and combinations thereof. Experiment The following experiment is conducted to determine the relationship between HMB exposure and cytokine production. To induce production of cytokines, PBMCs, isolated from peripheral blood of 10 normal healthy donors, are stimulated for 24 hours with the T cell stimulant CD3/CD28. Cytokine production is analyzed using a Bio-plex Cytokine Assay. The Bio-Plex technology is based on antibody-antigen interactions, wherein fluorescently labeled beads conjugated with antibody directed against the cytokine of interest bind target cytokine to the bead. This bead-cytokine complex is then exposed to a biotinylated detection antibody and a streptavidin-PE (phycoerythrin) reporter molecule. The signal from the reporter molecule is directly proportional to the amount of cytokine present, thus enabling cytokine quantification. Each of the T cell-derived cytokines quantified in the experiment is described in the following table: Type 1 cytokinesInterleukin 2Growth factor for all subpopulations of T cells(IL-2)and also promotes the proliferation of activatedB cellsInterleukin 12Induces the synthesis of IFNγ, IL-2, and(IL-12)Tumor necrosis factor α (TNFα) from helperT cells committed to the production of type 1cytokines (Th1 cells), promotes the generation oflymphokine activated killer cells, inhibits thesynthesis of IgE productionInterferon γInfluences cell mediated mechanisms of cytotoxicity,(IFNγ)has antiviral and antiparasitic activities andinhibits the proliferation of transformed cellsGranulocyteStimulates the proliferation and differentiationMacrophageof neutrophilic, eosinophilic, and monocyticcolonylineages and activates the mature forms of thesestimulatingcell typesfactor(GM-CSF)Tumor necrosisInduces cytolysis and cytostasis of tumor cells,factor αenhances the proliferation of T cells, promotes(TNFα)the proliferation and differentiation of B cellsin the presence of IL-2Type 2 cytokinesInterleukin 4Promotes the proliferation and differentiation of(IL-4)activated B cellsInterleukin 5Promotes growth and differentiation of eosinophils(IL-5)Interleukin 13Down-modulates macrophage activity, reduces pro-(IL-13)inflammatory cytokine production, induces humanmonocyte differentiation and B cell differentiationand proliferationInterleukin 10Suppressive cytokine which down-regulates type 1(IL-10)cytokine production A t-test (paired sample, two-tailed) is performed in which a broad range of type 1 and type 2 cytokines are evaluated from cultures with HMB compared to cultures and without HMB. Significant dose response increases are then observed in the production of the following type 1 cytokines: IL-2 (5 mM and 10 mM HMB), IL-12 (5 mM and 10 mM HMB), and IFNγ, (5 mM and 10 mM HMB); the results of which are summarized in FIG. 1 . Concerning type 2 cytokine production, a significant decrease is seen in IL-10 production following 10 mM exposure to HMB (see FIG. 2 ), while HMB does not significantly affect the production of GC-CSF, TNFα, IL-4, IL-5, and IL-13. These results are summarized in FIG. 1 and FIG. 2 . The shifts in cytokine production favoring type 1 are summarized in FIGS. 3 , 4 , and 5 . Increases in IL-2 production relative to IL-4 and IL-10 production are demonstrated at HMB concentrations of 5 mM and 10 mM, while increased in IL-2 production relative to IL-5 and IL-13 production are demonstrated at HMB concentrations of 1 mM, 5 mM, and 10 mM ( FIG. 3 ). Increases in IL-12 production relative to IL-4, IL-5, IL-13, and IL-10 are demonstrated at HMB concentrations of 5 mM and 10 mM ( FIG. 4 ). Increases in IFNγ production relative to IL-4 and IL-10 are demonstrated at an HMB concentration of 10 mM, while relative to IL-5 increases are demonstrated at HMB concentrations of 5 mM and 10 mM ( FIG. 5 ) The data show that HMB exposure increases type 1 cytokine production (IL-2, IL-12, IFNγ) while reducing production of certain type 2 cytokines (IL-10) and not significantly affecting the production of other type 2 cytokines (GC-CSF, TNFα, IL-4, IL-5, IL-13). The net result, therefore, is a shift in type 1 and type 2 cytokine production in favor of type 1 cytokine production. EXAMPLES The following examples illustrate specific embodiments of the methods of the present invention, including some nutritional and other product forms suitable for use therein. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present invention, as many variations thereof are possible without departing from the spirit and scope of the invention. The nutritional compositions described below are representative examples of nutritional products suitable for use in the methods of the present invention. Each may be prepared by conventional methods of making nutritional emulsion, some examples of which are described in U.S. Patent Publication 20050215640A1, which description is incorporated herein by reference. Liquid Nutritional #1 (Weight Gain Formula)IngredientAmt (kg)IngredientAmt (kg)Water316Vitamin DEK0.04Ultratrace/trace min.0.06premixpremixCarrageenan0.03Potassium chloride0.072Soy lecithin0.6Na citrate2.89Sodium caseinate15.5Potassium iodide0.0001Calcium caseinate4.2Potassium citrate1.5Ca HMB2.6Corn syrup7.68monohydrateMaltodextrin53.6Milk protein isolate14Mg phosphate dibasic0.26Sardine oil6.9Ca phosphate tribasic0.99Ascorbic acid0.12Magnesium chloride1.2KOH 45% Soln0.13Sucrose11.9Taurine0.12Fructooligosaccharide5.9Water sol. vit. premix0.11Medium chain2.6Ascorbyl palmitate0.03triglyceridesCholine chloride0.25Canola oil1.5L-carnitine0.0681Soy oil0.87Flavor #11.657% Vitamin A palmitate0.007Flavor #20.27 Liquid Nutritional #2 (Low Glycemic Index Formula)Amt perAmt perIngredient1,000 kgIngredient1,000 kgWaterQSVitamin C584gmMaltodextrin56kgPotassium chloride530gmAcid casein41.09kgCholine chloride472.1gmFructose28kg45% KOH soln.402.5gmHigh oleic27.2kgUTM/TM premix369.3gmsafflower oilK phosphate333gmMaltitol syrup16kgCarnitine230.5gmMaltitol12.63kgGellan gum125gmFibersol 2E8.421kgTaurine100.1gmCaseinate6.043kgVitamin E99gmFOS4.607kgLutein Esters (5%)92gmSoy4.3kgWSV premix75.4gmpolysaccharideVit. DEK premix65.34gmCanola oil3.2kg30% Beta carotene8.9gmTricalcium2.8kgVitamin A8.04gmphosphatePyridoxine HCl3.7gmMg chloride2.4kgChromium chloride1.22gmLecithin1.6kgFolic acid0.64gmSodium citrate1.18kgPotassium iodide0.20gmPotassium citrate1.146kgCyanocobalamin0.013gmSodium hydroxide1.134kgVitamin C584gmMg phosphate1.028kgCalcium HMB5.7kgmonohydratem-inositol914gm Liquid Nutritional #3 (Pediatric Formula)Ingredientper 771 kgStock PIF SlurryHigh oleic safflower oil40.7kgSoy oil24.4kgMCT oil16.3kgLecithin840.2gMonoglycerides840.2gCarrageenan508.9gCaseinate32.8kgStock OSV BlendDEK premix83.3gVitamin A7.1gLutein esters (5%)92gStock PIW SlurryWater530kgCaseinate11.3kgWhey protein11.9kgStock MIN SlurryWater18kgCellulose gum1696gCalcium HMB monohydrate4.4kgMagnesium chloride2.7kgPotassium chloride1.0kgPotassium citrate2.7kgPotassium iodide0.25gDipotassium phosphate1.45kgFinal BlendPIW slurry251kgPIF slurry53kgMIN slurry12.6kgSodium chloride127.4gSucrose77.6kgTricalcium phosphate2.5kgWater167kgStock WSF SolnWater31.7kgPotassium citrate3.74gUTM/TM premix172.2gWSV premix134.1gm-inositol176.7gTaurine145.5gL-carnitine34.92gCholine chloride638.7gStock ascorbic acid soln.Water18.6kgAscorbic acid550.0g45% KOH341gStock vanilla soln.Water38.5kgVanilla flavor4.3kg Nutritional Liquid #4 (Nutritional Supplement)Ingredientper 1,000 kgIngredientper 1,000 kgWaterQSMagnesium558gmCorn Syrup33kgchlorideMaltodextrin28kgVanilla Flavor544gmSucrose19.4kgSodium Chloride272gmCaseinate8.7kgCarrageenan227gmCalcium HMB5.7kgCholine chloride218gmmonohydrateUTM/TM Premix165gmHigh Oleic4.1kgPotassium Chloride146gmSafflower OilAscorbic Acid145gmCanola Oil4.1kgSodium Citrate119gmSoy Protein3.7kgPotassium104gmWhey Protein3.2kgHydroxideCaseinate2.9kgLutein (5%)46gmCorn Oil2.0kgWSV Premix33gmTricalcium1.4kgVit DEK Premix29gmPhosphateVitamin A3.7gmPotassium Citrate1.3kgPotassium Iodide86mcgMagnesium952gmPhosphateLecithin658gm Liquid Nutritional #5 (Asthma and Allergy formula)kg perkg perIngredient1000 kgIngredient1000 kgIngredient waterQ.S.Natural Vitamin E0.645Borage oil61.1Micronized tri0.631Marine oil53.4calcium phosphateMilk protein isolate30.4Tocopherol-20.600Sucrose11.7antioxidantWhey protein conc.8.41Taurine0.456Gum arabic8.00Vanilla0.400Calcium HMB5.7Sucralose 25% sol0.375MonohydrateZinc Sulfate0.251Soy lecithin4.77Ascorbyl palmitate0.143Cellulose gum4.00Sodium chloride0.143Potassium citrate2.64Acesulfame K0.0750Orange Cream Flavor2.50Cupric sulfate0.0177Ascorbic acid1.13FD&C Red #30.0150Turmeric powder1.00B carotene 30%0.00992Sodium citrate0.901Vit. A palmitate0.00315KOH 45% solution0.799Sodium molybdate0.000529Orange Oil0.750Sodium selenate0.000441 Powder Nutritional #6 (Exercise Formula)Amount perAmount perIngredient Name1000 kgIngredient Name1000 kgWhey Protein282.051kgPotassium5.128kgConcentrateChlorideCalcium Caseinate192.308kgSalt3.205kgMaltodextrin165.416kgXanthan Gum3.205kgMilk Protein138.782kgCholine Bitartrate2.782kgIsolate41% cholineDutch Cocoa 10/1276.932kgAcesulfame K2.718kgSunflower Oil21.474kgVanilla1.923kgCreamerDisodium PhosphateMyoplex Oil19.231kgAnhydrous1.667kgPreBlendMicroChill WPI1.282kgChocolate Cream15.256kgBeta Carotene1.128kgCalcium HMB13.157kg1% CWSmonohydrateSucralose692.3gOat Fiber10.897kgPotassium Citrate641.0gTricalcium8.526kg38% KPhosphateAlpha Ketoglutaric321.0gVitamin Mineral8.462kgAcidPreblendEgg Albumin321.0gDipotassium8.333kgPowderPhosphateL-Glutamine321.0gRich Dark Chocolate7.051kgTaurine321.0gCarrageenan CSM 26.474kg Working Example I A 28-year old individual who suffers from seasonal allergies in the spring is given 0.25-1 g of HMB (Nutritional Liquid #5) four times a week for a year. The symptoms of seasonal allergies are reduced the following spring. Working Example II A 30-year old white male who normally has four exacerbations of asthma per year is administered 1-10 g of HMB (Nutritional Liquid #5) four times a week for a year. Exacerbation frequency decreases to once a year. Working Example III A 45-year old female who has undergone chemotherapy for ovarian cancer is administered 2-10 g of HMB (Nutritional Liquid #1) four times a week for a year. One year later the ovarian cancer has not returned. Working Example IV A 50-year old male diagnosed with and has been treated for kidney tumors is administered 750 mg of HMB (capsules) four times a week for a year. Six months later the tumor has not spread to other parts of the individual's body. Working Example V A 42-year old female diagnosed with and treated for melanoma is administered 1 g of HMB 4 times ((Nutritional Liquid #1) a week for a year. Six months later the melanoma has not spread to other parts of the individual's body. Working Example VI A 37-year old male suffering from severe symptoms of psychological stress as a result of a burn injury is administered 500 mg (Nutritional Liquid #1) of HMB 4 times a week for a year. One year later the symptoms of psychological stress are reduced. Working Example VII A 29-year old female suffering from symptoms of surgical stress is administered 200 mg of HMB (Nutritional Liquid #2) 7 times a week for 2 months. Two months later the symptoms of surgical stress are reduced. Working Example VIII A 25-year old male suffering from symptoms of pre-surgical stress is administered 200 mg of HMB (capsules) once a day for 3 weeks preceding the individual's scheduled surgery. At the end of the 3 weeks, symptoms of pre-surgical stress are reduced. Working Example IX A 24-year old male suffering from moderate persistent asthma is tested to determine the individual's FEV 1 percentage value and the value is recorded. The individual is then administered 5-10 g of HMB 4 times ((Nutritional Liquid #5) a week for a year. One year later the individual's FEV 1 has not decreased and symptoms of asthma are reduced. Working Example X A 33-year old male suffering from mild intermittent asthma is tested to determine the individual's FEV 1 percentage value and a value of 83% is recorded. The individual is then administered 1.5-6 g of HMB 4 times (Nutritional Liquid #5) a week for a year. One year later the individual's FEV 1 remains above 80% and symptoms of asthma are reduced. Working Example XI A 14-year old female with a family history of seasonal allergies shows no signs of suffering from seasonal allergies. The individual is administered 0.1-1.5 g of HMB (Nutritional Liquid #3) once a day for 6 months. Six months later the individual still shows no signs of suffering from seasonal allergies. Working Example XII A 16-year old male with a family history of asthma shows no signs of suffering from the symptoms of asthma. The individual is administered 250 mg of HMB (Nutritional Liquid #4) once a day for 6 months. Six months later the individual still shows no signs of suffering from symptoms of asthma. Working Example XIII A 72 year old male, after conventional treatment for and recovery from pneumonia, is administered 250 mg of HMB (Nutritional Liquid #1) once a day for 6 months. During those six months, the individual remains free of respiratory tract infections, including any recurrence of pneumonia. Working Example XIV A 24-year old male is training for the New York Marathon. During his training period and for 3 months following the event he takes two servings per day of Nutritional formula #6 (containing 1 gram HMB per serving). Contrary to his previous year's experience, he does not experience any respiratory infections during this intense training regimen (such infections reflect the immune suppression that is known to be associated with extreme physical training programs).","lang":"en","source":"USPTO_FULLTEXT","data_format":"ORIGINAL"}},"description_lang":["en"],"has_description":true,"has_docdb":true,"has_inpadoc":true,"has_full_text":true,"biblio_lang":"en"},"jurisdiction":"US","collections":[],"usersTags":[],"lensId":"120-954-513-287-333","publicationKey":"US_8796333_B2","displayKey":"US 8796333 B2","docAssets":{"lensId":"120-954-513-287-333","pdfUrl":"https://www.lens.org/images/patent/US/8796333/B2/US_8796333_B2.pdf","images":[{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000001.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000001.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000002.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000002.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000003.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000003.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000004.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000004.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000005.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000005.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000006.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000006.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000007.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000007.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000008.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000008.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000009.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000009.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000010.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000010.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000011.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000011.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000012.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000012.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000013.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000013.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000014.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000014.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000015.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000015.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000016.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000016.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000017.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000017.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000018.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000018.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000019.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000019.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000020.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000020.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000021.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000021.png"},{"thumb":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/10pc/00000022.png","full":"https://s3-us-west-2.amazonaws.com/lens-resource/patent/US/B2/8796/8796333/image/page/full/00000022.png"}],"fallover":false},"countryName":"USA","inventorModel":{"inventors":[{"name":{"value":"THOMAS DEBRA L","valueNormalised":"Thomas Debra L"},"inventorship":null},{"name":{"value":"MUKERJI PRADIP","valueNormalised":"Mukerji Pradip"},"inventorship":null}],"inventorships":[],"unmatchedInventorships":[],"activeUserHasInventorship":false},"simpleFamilyId":190199778,"citesPatentCount":99,"countrySpec":{"countryName":"USA","description":"GRANTED PATENT AS SECOND PUBLICATION [FROM 2001 ONWARDS]","rule":"pubdate:AFTER:01-01-2001","docType":"GRANTED_PATENT"},"pageTitle":"US 8796333 B2 - Method of using β-hydroxy-β-methylbutyrate to treat a condition","documentTitle":"Method of using β-hydroxy-β-methylbutyrate to treat a condition"},"claims":{"source":"xml_claims","claims":[{"lines":["A method of treating an individual having a condition characterized by a higher relative ratio of type 2 cytokines to type 1 cytokines, the method comprising administering to the individual a composition comprising an effective amount of β-hydroxy-β-methylbutyrate to increase the relative ratio of type 1 to type 2 cytokines, wherein said treating consists of at least one of delaying the onset of said condition and reducing the severity of symptoms of said condition, and wherein said condition is selected from the group consisting of allergy and asthma."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the level of type 1 cytokines is increased by the administration of β-hydroxy-β-methylbutyrate without an increase in type 2 cytokines."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.1 grams to 10 grams per day."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 3 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.5 grams to 10 grams per day."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 0.5 grams to 5.0 grams per day."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5 wherein the effective amount of β-hydroxy-β-methylbutyrate ranges from 1.0 grams to 3.5 grams per day."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the composition further comprises one or more of fat, protein, and carbohydrate."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the condition is an allergy."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8 wherein the amount of β-hydroxy-β-methylbutyrate is effective to ameliorate symptoms of said allergy."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 8 wherein the allergy is selected from the group consisting of hay fever, food allergies, allergic conjunctivitis, atopic dermatitis, and inhalant allergies."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the condition is asthma."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is effective to ameliorate symptoms of said asthma."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is effective to prevent a decrease in forced expiratory volume in 1 second (FEV1)."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 11 wherein the amount of β-hydroxy-β-methylbutyrate is sufficient to maintain basal forced expiratory volume in 1 second (FEV1) above 80%."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the type 1 cytokine is selected from the group consisting of interferon-γ, interleukin 2, and interleukin 12."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 15 wherein the type 1 cytokine is interferon-γ or interleukin 2."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the type 2 cytokine is selected from the group consisting of interleukin 4, interleukin 5, interleukin 13, and interleukin 10."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 17 wherein the type 2 cytokine is interleukin 4."],"number":18,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1 wherein the composition further comprises a mineral selected from the group consisting of calcium, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, potassium, molybdenum, chromium, chloride, and combinations thereof."],"number":19,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}